Innovus Pharmaceuticals 10-K 28 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 24, 2014	Jun. 28, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'INNOVUS PHARMACEUTICALS, INC.	'	'
Entity Central Index Key	'0001411879	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Trading Symbol	'INNV	'	'
Entity Common Stock, Shares Outstanding	'	23,399,557	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$3,084,356

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
ASSETS	'	'
Cash	$33,374	$18,445
Accounts receivable	216,641	0
Prepaid Expenses	35,272	0
Deposits	21,200	0
Inventory	177,851	'
Total Current Assets	484,338	18,445
OTHER ASSETS	'	'
Property & Equipment, net of accumulated depreciation of ($526,584)	78,973	'
Deposits	21,919	'
Goodwill	421,372	0
Intangible assets, net of accumulated amortization	873,567	0
CIRCUMserum License, net of accumulated amortization	233,264	0
TOTAL ASSETS	2,113,433	18,445
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Accounts payable	143,756	1,602
Accrued compensation	395,667	0
Deferred revenue	175,569	0
Accrued interest payable (current portion)	3,224	0
Promissory notes	370,000	50,000
Total Current Liabilities	1,088,216	51,602
NON-CURRENT LIABILITIES	'	'
Accrued interest payable (non-current portion)	57,820	16,596
Convertible debentures - related parties (non-current portion), net of debt discount	511,465	162,668
Contingent Consideration	308,273	0
Total Non-Current Liabilities	1,083,286	179,264
TOTAL LIABILITIES	2,171,502	230,866
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' EQUITY (DEFICIT)	'	'
Common stock: 150,000,000 shares authorized, at $0.001 par value, 21,548,456 and 16,197,782 shares issued and outstanding, respectively	21,549	16,198
Additional paid-in capital	6,531,110	2,220,202
Deficit accumulated during the development stage	-6,405,000	-2,448,821
Total Stockholders' Equity (Deficit)	147,659	-212,421
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$2,113,433	$18,445

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property & Equipment, net of accumulated depreciation (in dollars)	$526,584	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	21,548,456	16,197,782
Common stock, shares outstanding	21,548,456	16,197,782

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		62 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
REVENUES	'	'	'
Product sales	$6,641	$0	$6,641
COST OF GOODS SOLD	1,821	0	1,821
GROSS PROFIT	4,820	0	4,820
OPERATING EXPENSES	'	'	'
Research and development	92,923	2,000	173,883
Investment banking fees	0	0	1,954,865
General and administrative	3,800,830	217,484	4,246,749
Total Operating Expenses	3,893,753	219,484	6,375,497
LOSS FROM OPERATIONS	-3,888,933	-219,484	-6,370,677
INTEREST EXPENSE	-67,246	-17,031	-175,562
Total Other Expense	-67,246	-17,031	-175,562
NET LOSS	($3,956,179)	($236,515)	($6,546,239)
BASIC LOSS AND DILUTED LOSS PER SHARE (in dollars per share)	($0.23)	($0.02)	'
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED (in shares)	17,329,899	11,999,597	'

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (Deficit) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit during Development Stage [Member]
Balance at Dec. 31, 2008	$0	$0	$0	$0
Balance (in shares) at Dec. 31, 2008	'	0	'	'
Common stock issued in FasTrack asset purchase	26,020	13,372	12,648	0
Common stock issued in FasTrack asset purchase (in shares)	'	13,372,284	'	'
Common stock issued in Sorrento business combination	11,000	0	11,000	0
Deemed distribution for the value of assets acquired from Apricus Bio	-396,878	0	0	-396,878
Net loss	-27,370	0	0	-27,370
Balance at Dec. 31, 2009	-387,228	13,372	23,648	-424,248
Balance (in shares) at Dec. 31, 2009	'	13,372,284	'	'
Common stock issued for compensation of board members	750	382	368	0
Common stock issued for compensation of board members (in shares)	'	381,761	'	'
Deemed contribution for the value of assets sold to Apricus Bio	204,896	0	204,896	0
Net loss	-69,923	0	0	-69,923
Balance at Dec. 31, 2010	-251,505	13,754	228,912	-494,171
Balance (in shares) at Dec. 31, 2010	'	13,754,045	'	'
Common stock issued for services	7,000	134	6,866	0
Common stock issued for services (in shares)	'	134,364	'	'
Common stock issued for compensation of officer	1,638	834	804	0
Common stock issued for compensation of officer (in shares)	'	833,668	'	'
Forgiveness of interest by Apricus Bio	4,021	0	4,021	0
Contribution to capital arising from conversion of convertible promissory notes held by Apricus Bio at Merger date pursuant to terms of convertible note, resulting in the future issuance of 135,888 shares of common stock in March 2012 to Apricus Bio	538,117	0	538,117	0
Common stock issued for net assets acquired in reverse-merger	-61,725	1,325	-63,050	0
Common stock issued for net assets acquired in reverse-merger (in shares)	'	1,325,125	'	'
Issuance of warrants to investment banker for services	1,904,865	0	1,904,865	0
Reclassification of shares issuable to FasTrack shareholders pursuant to rescission offer	-28,926	-14,722	-14,204	0
Reclassification of shares issuable to FasTrack shareholders pursuant to rescission offer (in shares)	'	-14,722,077	'	'
Net loss	-2,256,252	0	0	-2,256,252
Balance at Dec. 31, 2011	-142,767	1,325	2,606,331	-2,750,423
Balance (in shares) at Dec. 31, 2011	'	1,325,125	'	'
Common stock issued on conversion of Apricus Bio promissory note (see contribution recognition in 2011)	0	136	-136	0
Common stock issued on conversion of Apricus Bio promissory note (see contribution recognition in 2011) (in shares)	'	135,888	'	'
Common stock issued for cash	100,500	134	100,366	0
Common stock issued for cash (in shares)	'	134,000	'	'
Common stock issued upon conversion of debt	12,435	17	12,418	0
Common stock issued upon conversion of debt (in shares)	'	16,580	'	'
Expiration of FasTrack rescission offer and resultant reclassification to stockholders deficit	28,926	14,722	14,204	0
Expiration of FasTrack rescission offer and resultant reclassification to stockholders deficit (in shares)	'	14,722,077	'	'
Common stock and related contribution eliminated upon settlement agreement with Apricus Bio	0	-136	-537,981	538,117
Common stock and related contribution eliminated upon settlement agreement with Apricus Bio (in shares)	'	-135,888	'	'
Cash payment received pursuant to related-party settlement agreement	25,000	0	25,000	0
Net loss	-236,515	0	0	-236,515
Balance at Dec. 31, 2012	-212,421	16,198	2,220,202	-2,448,821
Balance (in shares) at Dec. 31, 2012	'	16,197,782	'	'
Common stock issued for services	498,841	1,018	497,823	0
Common stock issued for services (in shares)	'	1,017,641	'	'
Stock compensation expense	2,254,898	0	2,254,898	0
Common stock issued for purchase of CircumSerum License	250,000	631	249,369	0
Common stock issued for purchase of CircumSerum License (in shares)	'	631,313	'	'
Common stock issued for cash	134,639	417	134,222	0
Common stock issued for cash (in shares)	'	416,841	'	'
Common stock issued upon conversion of debt	51,458	83	51,375	0
Common stock issued upon conversion of debt (in shares)	'	83,103	'	'
Beneficial conversion feature	165,892	0	165,892	0
Common stock issued for acquisition	960,530	3,202	957,328	'
Common stock issued for acquisition (in shares)	'	3,201,776	'	'
Net loss	-3,956,179	0	0	-3,956,179
Balance at Dec. 31, 2013	$147,659	$21,549	$6,531,110	($6,405,000)
Balance (in shares) at Dec. 31, 2013	'	21,548,456	'	'

Statements_of_Stockholders_Equ1

Statements of Stockholders' Equity (Deficit) [Parenthetical] (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Common Stock, Capital Shares Reserved for Future Issuance	'	135,888
Development Stage Entities, Equity Issuance, Per Share Amount (in dollars per share)	$0.75	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		62 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'	'
Net loss	($3,956,179)	($236,515)	($6,546,239)
Adjustments to reconcile net loss to net cash used by operating activities:	'	'	'
Stock compensation	2,254,898	'	2,254,898
Common stock issued for services	498,840	0	508,228
Value of warrants granted to investment banker	0	0	1,904,865
Accretion of debt discount	16,215	0	16,215
Non-cash interest expense (including a discount on conversion of Apricus Bio convertible notes of $48,920)	0	0	91,897
Promissory note issued for services rendered	0	0	50,000
Research and development expense recognized upon purchase of SSAO inhibitor assets	0	0	20,000
Expenses paid on behalf of the Company by Apricus Bio	0	0	25,990
Amortization of Intangibles	18,608	'	18,608
Changes in operating assets and liabilities, net of acquisition amounts	'	'	'
Accounts receivable	-138,195	0	-138,195
Prepaid Expenses	-18,910	0	-18,910
Deposits	-43,119	0	-43,119
Inventory	2,590	'	2,590
Accounts payable	103,823	-85	105,425
Accrued compensation	395,667	0	395,667
Interest payable	45,908	17,031	62,503
Deferred revenue	175,569	0	175,569
Related-party payable	0	-12,500	0
Net Cash Used in Operating Activities	-644,286	-232,069	-1,114,009
CASH FLOWS FROM INVESTING ACTIVITIES	'	'	'
Acquisition of Semprae Inc, cash received	3,749	0	3,749
Purchase of Intangible Assets	-4,149	'	-4,149
Net Cash used in Investing Activities	-400	0	-400
CASH FLOWS FROM FINANCING ACTIVITIES	'	'	'
Proceeds from issuance of loans from officers	0	0	23,603
Repayment of loans from officers	0	0	-23,603
Proceeds from notes payable	350,000	0	350,000
Proceeds from related-party settlement agreement	0	25,000	25,000
Proceeds from stock issued for cash	134,639	100,500	235,139
Proceeds from convertible debt	50,000	0	50,000
Proceeds from convertible debt - related party	518,475	100,000	881,143
Repayment of assumed debt related to acquistion of Semprae	-343,500	'	-343,500
Repayment of Dawson James Note	-50,000	0	-50,000
Net Cash Provided by Financing Activities	659,614	225,500	1,147,782
NET CHANGE IN CASH	14,928	-6,569	33,373
CASH AT BEGINNING OF PERIOD	18,445	25,014	0
CASH AT END OF PERIOD	$33,374	$18,445	$33,374

ORGANIZATION_AND_SUMMARY_OF_SI

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Organization
	Innovus Pharmaceuticals, Inc., together with its subsidiaries (collectively referred to as “Innovus” or the “Company”) is an emerging pharmaceuticals company that delivers innovative and uniquely presented and packaged health solutions through its over-the-counter medicines and consumer and health products.  Innovus is located in La Jolla, California.  In its current state, the Company considers itself in a development stage but progressing into the commercial stage in the first quarter of 2014, based on the expected launch of two of its products for sexual dysfunction and arthritis pain relief in the US and other territories.
	Corporate History
	Reverse Merger between North Horizon and FasTrack
	Innovus Pharma was incorporated as North Horizon, Inc. in 1959 as a Utah corporation and changed its domicile in 2007 to the State of Nevada. In December 2011, North Horizon merged with FasTrack Pharmaceuticals, Inc. North Horizon had no ongoing business at the time of the merger, and FasTrack had a pipeline of one commercial stage product, Apeaz, and one pre-clinical product candidate, Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1, or SSAO/VAP-1, antagonist intended for psoriasis and arthritis. A reverse merger occurred for financial reporting purposes, and the Company changed its name to Innovus Pharmaceuticals, Inc.
	Merger with Semprae Laboratories, Inc.
	On December 24, 2013, Innovus Pharma entered into an agreement and plan of merger (the “Merger Agreement”) with Innovus Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Innovus Pharma (“Merger Sub”), Semprae Laboratories, Inc., a Delaware corporation (“Semprae”), certain stockholders of Semprae and Quaker Bioventures II, L.P., a principal stockholder of Semprae, pursuant to which, on the same date, Merger Sub merged into Semprae with Semprae continuing as the surviving corporation and a wholly-owned subsidiary of Innovus Pharma.
	Proprietary Product and Technology Portfolios
	The Company is an emerging pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription pharmaceutical products and consumer care health products backed with strong scientific and clinical evidence. The Company’s products are focused in the men’s and women’s health and vitality, and in the pain management therapeutic categories.
	Pharmaceutical and Consumer Care Products
	Our pharmaceutical and consumer care product business is currently made up of over-the-counter (OTC) and consumer care health products. We are in the process of marketing our products in the US and other countries.
	EjectDelay
	EjectDelay™ is an OTC monograph compliant benzocaine based topical gel for treating premature ejaculation by desensitizing the nerves in the penis, allowing a man to delay ejaculation time.
	Apeaz™
	Apeaz™ is an OTC monograph compliant topical cream for the relief of arthritis pain among other inflammatory conditions which contains methylsulfonylmethane and glucosamine.
	CIRCUMserum™
	We acquired the foreign distribution rights to CIRCUMserum™, a non-medicated cream which moisturizes the head of the penis for enhanced feelings of sensation and greater sexual satisfaction from Centric Research Institute (“CRI”). CIRCUMserum is a patent-pending   blend of essential oils and ingredients generally recognized as safe that recently commenced marketing in the United States.
	Zestra® and Zestra® Glide
	We acquired Zestra® and Zestra® Glide, through the acquisition of Semprae Laboratories, Inc. Zestra® is a non-medicated patented natural product that helps with sexual dysfunction in women by increasing nerve conduction and vascular smooth muscle dilation, resulting in increasing desire, arousal in women. Zestra® Glide is a clinically tested water based lubricant.
	Xyralid™
	Xyralid™ is an OTC monograph compliant lidocaine based spray in development for the relief of hemorrhoids pain among other inflammatory conditions.
	Basis of Presentation and Principles of Consolidation
	These condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), and include all assets, liabilities, revenues and expenses of the Company and its wholly-owned subsidiary: FasTrack Pharmaceuticals, Inc.  All material intercompany transactions and balances have been eliminated. Certain items have been reclassified to conform to the current presentation.
	Use of Estimates
	The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods.  Such management estimates include equity-based instruments, realizability of deferred tax assets, and intangible assets. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions.
	Liquidity
	Historically, we have funded losses from operations through the sale of equity and issuance of debt instruments, primarily to related parties including directors and officers. Combined with minimal revenue, these funds have provided us with the resources to operate our business, to begin to sell and support our products, attract and retain key personnel, and add new products to our portfolio. To date, we have experienced net losses and negative cash flows from operations each year since our inception. Through December 31, 2013, we had an accumulated deficit of $6,405,000.
	As of December 31, 2013, we had $33,374 in cash and cash equivalents. We have raised funds through the issuance of convertible debentures and sale of common stock. We have also utilized equity instruments where possible to pay for services from vendors and consultants. Furthermore, we have an arrangement with our Chief Executive Officer which provides for a line of credit to us in the amount of up to $1,000,000  through the earlier of our successful completion of a financing of $4 million, or July 1, 2016 and permits the deferral of his salary payments as described below. Based upon these factors and arrangements, we believe our cash and cash equivalents will be sufficient to fund our operations until at least December 31, 2014. We expect that our short-term operating expenses will be primarily expenses to sell and support our products and attract and retain key personnel.
	Other potential sources of liquidity in the short term include payments from our existing partners for license fees, entering into new collaborative, licensing or commercial agreements in additional territories, and revenues from the sale of our products.
	In addition to payments from our current licensing and commercial agreements, as well as funds from public and private financial markets, potential sources of liquidity in the long term include milestone, royalty and other payments from any future commercial agreements or licensees and revenues from sales of our own products. If we determine it is advisable to raise additional funds, we do not know whether adequate funding will be available to us or, if available, that such funding will be available on acceptable terms.
	Fair Value Measurement
	The Company’s financial instruments are cash, accounts receivable, accounts payable, accrued liabilities, convertible debentures and a convertible debt instrument. The recorded values of cash, trade accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. We believe the recorded values of convertible debentures and convertible debt, net of the discount, approximate the fair value as the interest rate (stated or effective) approximates market rates for similar types of instruments.
	The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows:
		⋅	Level 1 measurements are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
		⋅	Level 2 measurements are inputs other than quoted prices included in Level 1 that are observable either directly or indirectly.
		⋅	Level 3 measurements are unobservable inputs.
	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities of three months or less when purchased.
	Concentration of Credit Risk and Major Customers
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash held with financial institutions may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation (“FDIC”) on such deposits.
	Accounts receivable consist primarily amounts receivable from Ovation Pharma under our licensing agreement ( See note 4). The Company also requires a percentage of payment in advance for product orders with its larger partners. The Company has not yet recognized revenue under these arrangements. The Company also performs ongoing credit evaluations of its customers and generally does not require collateral.  There have been no write-offs of trade accounts receivable during the periods presented.
	The following table identifies customers with accounts receivable that individually exceed 10% of the Company’s total accounts receivable at December 31, 2013:
	Ovation Pharma		135,035		52	%
	Retail Customer A		37,963		15	%
	Concentration of Suppliers
	The Company has manufacturing relationships with a number of vendors or manufacturers for its products including: CIRCUMserum™,  EjectDelay™,  Zestra® and the ApeazTM line of products.  Pursuant to these relationships, the Company purchases product through purchase orders with its manufacturers. The Company is in the process of entering into more formal agreements with certain of these manufacturers.
	Business Combinations
	For business combinations the Company utilizes the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations. These standards require that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based on their respective fair values at the date of acquisition. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred.
	The Company recognizes separately from goodwill the fair value of assets acquired and the liabilities assumed. Goodwill as of the acquisition date is measured as the excess of consideration transferred and the acquisition date fair values of the assets acquired and liabilities assumed. While the Company uses its best estimates and assumptions as a part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the Company's estimates are subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may retroactively record adjustments to the fair value of the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company's consolidated statements of operations.
	Inventory
	Inventory, consisting primarily of finished goods, is valued at the lower of cost or market where cost is determined using the first-in, first-out method. The inventory balance at 2013 is primarily comprised of finished goods for Zestra® and Zestra® Glide from the acquisition of Semprae (See Note 3) . Inventory is shown net of obsolescence and allowance for reducing the inventory cost to market. Obsolescence of inventory is determined based on shelf life or potential product replacement.
	Property and Equipment
	Property and equipment are recorded at historical cost less accumulated depreciation. Depreciation is computed using the straight-line method over their estimated useful lives. The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.
	Intangible Assets
	Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives, which range in term from 7 to 14 years. The useful life of the intangible asset is evaluated each reporting period to determine whether events and circumstances warrant a revision to the remaining useful life.
	Goodwill
	The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit's carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significant!y i!npact those judgments in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition commenced on December 24, 2013. There was no impairment of goodwill for the year ended December 31, 2013.
	The purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired from Semprae. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below.
		⋅	The fair value of current assets and liabilities approximated their book value.
	The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share.
	Intangible assets consist of the following at December 31, 2013:
						Accumulated				Useful Lives
		Amount			Amortization		Net Amount		(years)
Patents and trademarks		$	264,320		$	-722	$	263,598	14-Jul
Customer contracts			611,119			-1,150		609,969	10
CIRCUMserum™ license			250,000			-16,736		233,264	10
Outstanding at December 31, 2013			1,125,439			-18,608		1,106,831
Expected amortization is approximately $112,000 for each of the next five years, and $556,000 thereafter.
Long-Lived Assets
The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company evaluates assets for potential impairment by comparing estimated future undiscounted net cash flows to the carrying amount of the asset. If the carrying amount of the assets exceeds the estimated future undiscounted cash flows, impairment is measured based on the difference between the carrying amount of the assets and fair value.
Beneficial Conversion Features and Debt Discounts
If a conversion feature of conventional convertible debt is not accounted for separately as a derivative instrument and provides for a rate of conversion that is below market value, this feature is characterized as a beneficial conversion feature (“BCF”). A BCF is recorded by the Company as a debt discount. The Company amortizes the discount to interest expense over the life of the debt using the effective interest rate method. The Company’s 8% convertible debentures and convertible line of credit contain an embedded conversion feature of the notes. (See Note 5)
Income Taxes
Income taxes are provided for using the asset and liability method whereby deferred tax assets and liabilities are recognized using current tax rates on the difference between the financial statement carrying amounts and the respective tax basis of the assets and liabilities. The Company provides a valuation allowance on deferred tax assets when it is more likely than not that such assets will not be realized.
The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting this standard, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognized interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying statements of operation. Accrued interest and penalties are included within the related tax liability in the consolidated balance sheets.
Revenue Recognition and Deferred Revenue
The Company generates revenues from product sales and the licensing of the rights to market and commercialize its products.
Product Sales. The Company ships product to its customers pursuant to purchase agreements or orders. Revenue from sales transactions where the buyer has the right to return the product shall be recognized at the time of sale only if (1) the seller’s price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the seller, or the buyer is obligated to pay the seller and the obligation is not contingent on resale of the product, (3) the buyer’s obligation to the seller would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the seller, (5) the seller does not have significant obligations for future performance to directly bring about resale of the product by the buyer and (6) the amount of future returns can be reasonably estimated.
License Arrangements.  Payments received by the Company under license arrangements to market and commercialize its products may include non-refundable upfront fees, license fees, milestone payments for specific achievements designated in the agreements, and royalties on sales of products. The Company considers a variety of factors in determining the appropriate method of accounting under its license arrangements, including whether the various elements can be separated and accounted for individually as separate units of accounting.
Sales Allowances
The Company accrues for product returns, volume rebates and promotional discounts in the same period the related sale is recognized.
The Company’s product returns accrual is primarily based on estimates of future product returns over the period customers have a right of return, which is in turn based in part on estimates of the remaining shelf-life of products when sold to customers. Future product returns are estimated primarily based on historical sales and return rates. The Company estimates its volume rebates and promotional discounts accrual based on its estimates of the level of inventory of its products in the distribution channel that remain subject to these discounts. The estimate of the level of products in the distribution channel is based primarily on data provided by the Company’s customers.
In all cases, judgment is required in estimating these reserves, and actual claims for rebates, returns and promotional discounts could be materially different from the estimates.
The Company provides a customer satisfaction warranty on all of its products to customers for a specified amount of time after product delivery. Estimated return costs are based on historical experience and estimated and recorded when the related sales are recognized. Any additional costs are recorded when incurred or when they can reasonably be estimated.
The estimated reserve for sales returns and allowances, which is included in accounts payable and accrued liabilities, was insignificant at December 31, 2013 and December 31, 2012.
Cost of Goods Sold
Cost of goods sold includes the cost of inventory, royalties and inventory reserves. The Company is required to make royalty payments based upon the net sales of its marketed products, Zestra® and CIRCUMserum ™.
Research and Development Costs
Research and development (“R&D”) costs, including research performed under contract by third parties, are expensed as incurred. Major components of R&D expenses consist of testing, clinical trials, material purchases and regulatory affairs.
Stock-based Compensation
The Company accounts for stock based compensation in accordance with ASC 718, Stock Based Compensation, which requires the recognition of the fair value of stock compensation as an expense in the calculation of net income. ASC 718 requires that stock-based compensation expense be based on awards that are ultimately expected to vest. Stock-based compensation for the years ended December 31, 2013 and 2012 have been reduced for estimated forfeitures. When estimating forfeitures, voluntary termination behaviors, as well as trends of actual option forfeitures, are considered. To the extent actual forfeitures differ from the Company’s current estimates, cumulative adjustments to stock-based compensation expense are recorded.
Except for transactions with employees and directors that are within the scope of ASC 718, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.
Equity Instruments Issued to Non-Employees for Services
Issuances of the Company’s common stock for services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants is determined at the earlier of (a) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) (b) the date at which performance is complete, and is based upon the quoted market price of the common stock at the date of issuance (See Note 7).
Comprehensive Loss
Comprehensive loss consists of net loss and other gains and losses affecting stockholders’ equity (deficit) that, under U.S. GAAP, are excluded from net loss. Comprehensive loss was the same as net loss for the year ended December 31, 2013 and 2012 as the Company has no other comprehensive income.
Earnings per Share
Basic earnings per share are computed by dividing net loss by the weighted average number of common shares outstanding during the period presented. Diluted earnings per share are computed using the weighted average number of common shares outstanding during the periods plus the effect of dilutive securities outstanding during the periods. For the year ended December 31, 2013 and 2012, basic earnings per share are the same as diluted earnings per share as a result of the Company’s common stock equivalents being anti-dilutive.
The following reconciliation shows the anti-dilutive shares excluded from the calculation of basic and diluted loss per common share attributable to the Company for the year ended December 31, 2013 and 2012:
		As of December 31
		2013		2012
Gross number of shares excluded:
Restricted stock units		6,300,000		-
Stock options		21,000
Convertible notes payable		2,378,287		2,853,360
Warrants		380,973		380,973
Total		9,080,260		3,234,333
New Accounting Pronouncements
In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“AOCI”). This standard requires reporting, in one place, information about reclassifications out of AOCI by component. An entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of AOCI by the respective line items of net income, but only if the amount is reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified to net income in their entirety, an entity is required to cross-reference to other currently required disclosures that provide additional detail about those amounts. The information required by this standard must be presented in one place, either parenthetically on the face of the financial statements by income statement line item or in a note. The adoption of ASU 2013-02 had no impact on the Company’s financial position or results of operations.

LICENSE_AGREEMENTS

LICENSE AGREEMENTS	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	NOTE 2 – LICENSE AGREEMENTS
	CRI License Agreement
	On April 19, 2013, the Company and CRI entered into an asset purchase agreement (the “CRI Asset Purchase Agreement”) pursuant to which the Company acquired:
		⋅	all of CRI’s rights in past, present and future CIRCUMserum™ product formulations and presentations, and
		⋅	an exclusive, perpetual license to commercialize CIRCUMserum™ products in all territories except for the United States.
	CRI has retained commercialization rights for CIRCUMserum™ in the United States.
	In consideration for such assets and license, the Company agreed to issue to CRI shares of the Company’s common stock valued at $250,000 within 10 days of the closing. The Company issued 631,313 shares to CRI in this regard. The Company will be required to issue to CRI shares of the Company’s common stock valued at an aggregate of $200,000 for milestones relating to additional clinical data received. The number of shares to be issued was or will be determined based on the average of the closing price for the 10 trading days immediately preceding the issue date. CRI will have certain “piggyback” registration rights with respect to the shares described above, which rights provide that, if the Company registers shares of its common stock under the Securities Act in connection with a public offering, CRI will have the right to include such shares in that registration, subject to certain exceptions. The Company recorded an asset totaling $250,000 related to the CRI Asset Purchase Agreement and will amortize this amount over its estimated useful life of 10 years. The Company has recorded amortization of $16,736 beginning in the fourth quarter of 2013 when we commenced usage.  The Company has recorded net sales of CIRCUMserum™ of $630, which relate to Ex US sales from CRI’s website.
	The CRI Asset Purchase Agreement also requires the Company to pay to CRI up to $7 million in cash milestone payments based on first achievement of annual net sales targets plus a royalty based on annual net sales. The obligation for these payments expires on April 19, 2023 or the expiration of the last of CRI’s patent claims covering the product or its use outside the United States, whichever is sooner. No sales milestones have been met under this agreement, and royalties owed to CRI were immaterial and included in net revenues.
	In connection with this transaction, the Company engaged a consultant to assist in the technology transfer and manufacturing of the product. In consideration of such services, the Company agreed to issue to the consultant shares of its common stock valued at an aggregate of $75,000 at various dates following the closing of the CRI transaction. In each case, the number of shares issuable is determined based on the average of the closing price of the Company’s common stock for the 10 trading days immediately preceding the issue date (see Note 7).
	Ovation Pharma Agreements
	On September 9, 2013, the Company entered into a license and distribution agreement with Ovation Pharma SARL (“Ovation”) under which it granted to Ovation an exclusive license to market and sell the Company’s topical treatment for reduced penile sensitivity, CIRCUMserum™, in Morocco. Ovation may pay the Company up to approximately $11.25 million upon achievement of commercial milestones. In addition, Ovation has agreed to certain upfront minimum purchases of CIRCUMserum™ based upon an agreed upon transfer price and yearly minimum purchases.
	On September 9, 2013 the Company entered into a second license and distribution agreement with Ovation under which it granted to Ovation an exclusive license to market and sell the Company’s topical premature ejaculation treatment, EjectDelay™, in Morocco. Ovation may pay the Company up to approximately $18.6 million allocated among a fixed upfront license fee and the achievement of regulatory and commercial milestones. In addition, Ovation has agreed to certain upfront minimum purchases of EjectDelayTM  ™ based upon an agreed upon transfer price and minimum yearly purchases.
	The Company determined that the fixed upfront license fee payment was a separate deliverable under the EjectDelay™ license and distribution agreement and therefore recorded a receivable on its balance sheet. There were no additional obligations or deliverables associated with the license.  However, as of December 31, 2013, as Ovation had not yet received necessary government authorization to make the payment, the Company will recognize the license fee when received. Subsequent to December 31, 2013, the Company has received $25,000 toward the payment of this license fee.

BUSINESS_ACQUISITIONS

BUSINESS ACQUISITIONS	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	NOTE 3- BUSINESS ACQUISITIONS
	Recapitalization Transaction
	On December 7, 2011 the Company consummated a combination wherein FasTrack Pharmaceuticals, Inc. (“FasTrack”), a corporation organized under the laws of the state of Delaware, merged with and into North Horizon, Inc., a Utah corporation.
	The combination (the “Agreement”) stipulated that the companies would undergo a combination whereby the surviving entity would be North Horizon. FasTrack then became a wholly-owned subsidiary of North Horizon. North Horizon then changed its name to Innovus Pharmaceuticals, Inc. The transaction has been accounted for as a reverse merger, whereby North Horizon is the legal acquirer and FasTrack is the legal acquiree and the accounting acquirer.
	As consideration for the business, the shareholders of FasTrack were allocated 15,238,938 shares (portion of which are subject to rescission election discussed in Note 1) of the Company’s post-split common stock (representing 92% ownership of Innovus); the shareholders of North Horizon held 1,325,125 shares (representing 8% ownership of Innovus). Included in the FasTrack shares are the 135,888 shares issuable to Apricus Bio upon conversion of their note (see Note 6), which were issued in March of 2012. All shares were issued to the FasTrack shareholders in March of 2012, due to the time required to gather signatures of each shareholder. As part of the recapitalization transaction, the Company assumed a liability of approximately $60,000 due to an officer of North Horizon.
	Purchase of Semprae Laboratories, Inc.
	On December 24, 2013 (the “Closing Date”), the Company, through its wholly-owned subsidiary, Innovus Acquisition Corporation, obtained 100% of the outstanding shares of Semprae Laboratories, Inc. (“Semprae”), in exchange for the issuance of 3,201,776 shares of the Company’s Common Stock, which shares represented fifteen percent (15%) of the total issued and outstanding shares of the Company as of the close of business on the Closing Date, whereupon Innovus Acquisition Corporation was renamed Semprae Laboratories, Inc. Also, the Company agreed to pay $343,500 to the New Jersey Economic Development Authority (“NJEDA”) as settlement-in-full for an outstanding loan of approximately $640,000 owed by the former stockholder’s of Semprae, in full satisfaction of the obligation to the NJEDA. In addition, the Company agreed to pay the Acquiree an annual royalty (“Royalty”) equal to five percent (5%) of the net sales from Zestra® and Zestra® Glide and any second generation products derived primarily therefrom (“Target Products”) up until the time that a generic version of such Target Product is introduced worldwide by a third party.
	The Company issued 3,201,776 shares of its Common Stock. The fair market value of the Company’s common stock as of the Closing Date was $0.30 per share, which results in a fair market value of $960,530 for the common stock issued to Semprae. The fair value of the shares of common stock issued were determined by quoted market prices that are considered to be Level 1 inputs under the fair value measurements and disclosure guidance.
	The agreement to pay the annual Royalty resulted in the recognition of a contingent consideration. The fair value of the contingent consideration is based on preliminary cash flow projections and other assumptions. Based on the assumptions, the fair value of the Royalty was determined to be $308,273. The fair value of the royalty was determined by applying the income approach, using several significant unobservable inputs for projected cash flows and a discount rate. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance.
	The transaction has been accounted for as a business combination under the acquisition method of accounting. Accordingly, the tangible assets and identifiable intangible assets acquired and liabilities assumed have been recorded at fair value, with the remaining purchase price recorded as goodwill. The fair values of acquired assets and liabilities are based on preliminary cash flow projections and other assumptions. The preliminary fair values of acquired intangible assets were determined using several significant unobservable inputs for projected cash flows and a discount rate. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance.
	The agreement to pay the annual Royalty resulted in the recognition of a contingent consideration, which is recognized at the inception of the transaction, and subsequent changes to estimate of the amounts of contingent consideration to be paid will be recognized as charges or credits in the statement of operations. The fair value of the contingent consideration is based on preliminary cash flow projections, growth in expected product sales and other assumptions. Based on the assumptions, the fair value of the Royalty was determined to be $308,273 at the date of acquisition. The fair value of the royalty was determined by applying the income approach, using several significant unobservable inputs for projected cash flows and a discount rate of 40% commensurate with the Company’s cost of capital and expectation of the revenue growth for products at their life cycle stage. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. The fair value of contingent consideration didn’t change between December 24, 2013 (acquisition date) and December 31, 2013.
	As a result of the acquisition, the Company acquired all of Semprae’s assets and liabilities, including its two women’s products, which were added to the Company’s current portfolio of male sexual dysfunction products and other topical products. Semprae also maintains a number of international patents and trademarks on its two products.
	The aggregate purchase price consideration was as follows:
	Fair value of common stock issued to Semprae shareholders		$	960,530
	Fair value of royalty			308,273
	Net purchase price consideration		$	1,268,803
	The assets acquired and liabilities assumed at the transaction date are preliminary purchase price allocations based on the fair value and are summarized below:
	Cash and cash equivalents		$	3,749
	Accounts receivable			78,445
	Inventory			180,441
	Prepaid expenses			16,362
	Property and equipment			78,973
	Customer contracts			611,119
	Patents			99,894
	Trademarks			160,278
	Goodwill			421,372
	Accounts Payable			-38,330
	Debt			-343,500
	Net Purchase Price Consideration		$	1,268,803
	Common Stock			960,530
	Fair Market Value of Royalty			308,273
			$	1,268,803
	Supplemental Pro Forma Information for 2013 Acquisition (unaudited)
	The following unaudited supplemental pro forma information for the years ended December 31, 2013 and 2012 assumes the contribution of Semprae had occurred as of January 1, 2012, giving effect to purchase accounting adjustments. The pro forma data is for informational purposes only and may not necessarily reflect the actual results of operations had Semprae been operated as part of the Company since January 1, 2012.
			For the year		For the year
			ended December		ended December
			31, 2013		31, 2012
	Revenue		$	760,847	$	1,537,472
	Net Loss (1)			-4,375,108		-3,495,470
	Loss per common share -basic and diluted		$	-0.25	$	-0.23
	Shares used in computing net loss per common share			17,329,899		15,201,373
	-1	The pro forma net loss includes adjustments for interest expense related to the assumption of debt, and amortization expense related to the intangible assets acquired.
	Total revenue and net loss included in the consolidated statement of operations during the year ended December 31, 2013 for Semprae since the date of acquisition, is $6,010 and $6,331, respectively.

NOTES_PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2013
Notes Payable [Abstract]	'
Notes Payable [Text Block]	'
	NOTE 4- NOTES PAYABLE
	The following table summarizes the outstanding unsecured notes payable at December 31, 2013 and 2012:
		2013		2012
	Dawson James Promissory Note	$	-	$	50,000
	Lourmarin Corporation Note		350,000		-
	January 2012 Debenture Holder- not amended (See Note 5)		20,000		-
	Promissory Notes		370,000		50,000
	Dawson James Promissory Note
	On December 7, 2011 the Company entered into a promissory note with Dawson James Securities, Inc. (“DJS”) whereby, as compensation for consulting services rendered, the Company agreed to pay DJS a sum of $50,000. The principal was due December 6, 2012 and the note accrued interest at a rate of 8.0% per annum. The note was unsecured.
	On January 28, 2013, the Company paid DJS $54,548, which represents the principal and accrued interest due on the note, discharging the note in full.
	Lourmarin Corporation Note
	On December 23, 2013, the Company issued an 8% debenture to an unrelated third party accredited investor in the principal amount of $350,000 (the “Debenture”). The Debenture bears interest at the rate of 8% per annum. The principal amount and interest are payable on August 31, 2014. Dr. Bassam Damaj, the President and Chief Executive Officer of the Company, has personally guaranteed payment of the principal and interest under the Debenture in the case of any event of default by the Company.

CONVERTIBLE_DEBENTURES_RELATED

CONVERTIBLE DEBENTURES - RELATED PARTIES	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Related Party Debt Disclosure [Text Block]	'
	NOTE 5 – CONVERTIBLE DEBENTURES – RELATED PARTIES
	The following table summarizes the outstanding unsecured convertible deberntures issued to related parties at December 31, 2013 and 2012:
		2013		2012
	January 2012 Debentures	$	142,668	$	162,668
	January 2013 Debenture		70,000		-
	Line of Credit- Convertible Debenture		448,475		-
	Debt Discount, net of accretion		-149,678
	Convertible Debentures- related parties		661,143		162,668
	January 2012 Convertible Debentures
	In January 2012, the Company issued 8% convertible debentures in the aggregate principal amount of $174,668 (the “January 2012 Debentures”) to six individuals.  Under their original terms, the January 2012 Debentures were payable in cash at the earlier of January 13, 2013 or when the Company completes a financing with minimum gross proceeds of $4 million (the “Financing”), the holders had the right to convert outstanding principal and interest accrued into the Company’s securities that were issued to the investors in the Financing, and, in the event the Company defaulted on repayment, or if the Company failed to complete the Financing by January 13, 2013, the annual interest rate would increase to 13% and the holders would have the option to convert the principal and interest accrued into shares of the Company’s common stock at $0.05 per share. The Company does not have the right to pre-pay the January 2012 Debentures. One of the January 2012 Debentures, in the principal amount of $74,668, was issued to one accredited investor in exchange for the liabilities assumed from North Horizon, Inc. upon the 2011 reverse merger. The five other January 2012 Debentures, in an aggregate principal amount of $100,000, were issued in exchange for new cash infusion by five individuals, three of whom are members of the Company’s Board of Directors.
	Through December 31, 2012, $12,000 (plus accrued interest of $435) of the January 2012 Debentures were converted into 16,580 shares of common stock, leaving an aggregate principal balance of $162,668 at December 31, 2012.
	The Financing did not occur by January 13, 2013. However, in January 2013, the five remaining holders of the outstanding January 2012 Debentures agreed to extend the maturity date to January 14, 2014 at the same interest rate of 8% per annum, and to extend the date for optional conversion to common stock to January 14, 2014. In May and August 2013, four of the five holders of the outstanding January 2012 Debentures agreed to further extend the maturity date to July 1, 2014 at the same interest rate of 8% per annum, and to further extend the date for optional conversion to common stock to July 1, 2014.
	On November 11, 2013, four of the five holders of the outstanding January 2012 Debentures agreed to amend and restate the debentures to provide for automatic conversion into securities of the Company upon the earlier of either (a) the closing of the Financing and (b) July 1, 2016.
	The fifth holder of one of the January 2012 Debentures in the amount of $20,000 did not amend the debenture and it has been classified as a short term note payable as of December 31, 2013 (See Note 4).
	The January 2012 Debentures contain a beneficial conversion feature of the notes. The intrinsic value of the beneficial conversion feature at the date of issuance was determined by measuring the difference between the conversion price and the intrinsic value of the stock at the commitment date. The Company recorded a debt discount for the intrinsic value of the beneficial conversion feature which was limited to the proceeds with an offsetting increase to paid-in-capital. The beneficial conversion of $40,889 has been included in the balance sheet at December 31, 2013 as a discount to the related debt security, and is being accreted as non-cash interest expense over the expected term of the loan using the effective interest method.
	January 2013 Convertible Debenture
	In January 2013, the Company issued a convertible debenture in the principal amount of $70,000 to a director of the Company (the “January 2013 Debenture”). The terms of the January 2013 Debenture are identical to those of the January 2012 Debentures.
	On November 11, 2013, the holder of the outstanding January 2013 Debenture agreed to amend and restate the debenture to provide for automatic conversion into securities of the Company upon the earlier of either (a) the closing of the Financing and (b) July 1, 2016.
	The January 2013 Debenture contains a beneficial conversion feature related to the note. The intrinsic value of the beneficial conversion feature at the date of issuance was determined by measuring the difference between the conversion price and the intrinsic value of the stock at the commitment date. The Company recorded a debt discount for the intrinsic value of the beneficial conversion feature which was limited to the proceeds with an offsetting increase to paid-in-capital. The beneficial conversion of $18,651 has been included in the balance sheet at December 31, 2013 as a discount to the related debt security, and is being accreted as non-cash interest expense over the expected term of the loan using the effective interest method.
	Line of Credit – Convertible Debenture
	On January 22, 2013, the Company entered into a line of credit convertible debenture with its President and Chief Executive Officer (the “LOC Convertible Debenture”). Under the terms of its original issuance: (1) the Company could request to borrow up to a maximum principal amount of $250,000 from time to time; (2) amounts borrowed bore an annual interest rate of 8%; (3) the amounts borrowed plus accrued interest is payable in cash at the earlier of January 14, 2014 or when the Company completes a Financing; and (4) the holder had sole discretion to determine whether or not to make an advance upon the Company’s request.
	On March 18, 2013, the LOC Convertible Debenture was amended and restated. Under its amended and restated terms: (1) the Company could request to borrow up to $500,000; (2) amounts borrowed bore an annual interest rate of 8%; (3) the amounts borrowed plus accrued interest is payable in cash at the earlier of January 14, 2014 or when the Company completes a Financing; (4) the holder committed to advance funds (up to the maximum amount borrowable thereunder) to the Company upon its request if and to the extent the Company will have insufficient liquidity to meet any material payment obligations arising in the ordinary course of business as they come due; and (5) the holder’s funding commitment automatically terminated on the earlier of January 1, 2014 or when the Company completed a financing with minimum net proceeds of at least $500,000. In addition, the holder’s funding commitment increases by the gross amount of any cash salary, bonus or severance payments provided to the holder under his employment agreement with the Company. The holder’s salary has been accrued and not paid under the provision of such employment agreement stating that salary payments will be accrued and not paid for so long as payment of such salary would jeopardize the Company’s ability to continue as a going concern. Such balance was $448,475 at December 31, 2103.
	On May 6, 2013, the LOC Convertible Debenture was further amended to: (1) extend its maturity date from January 14, 2014 to July 1, 2014 (or, if earlier, when the Company completes a Financing); (2) increase the maximum principal amount borrowable thereunder from $500,000 to $1,000,000; and (3) change the automatic termination of the holder’s funding commitment to the earlier of July 1, 2014 or when the Company completes a financing with minimum net proceeds of at least $1,000,000. The other material terms of the debenture were not changed.
	On November 11, 2013, the Company and the holder of the LOC Convertible Debenture agreed to amend and restate its terms to provide that: (1) the debenture will automatically convert into securities of the Company upon the earlier of either (a) the closing of the Financing and (b) July 1, 2016 and (2) the holder’s funding commitment will automatically terminate on the earlier of either (a) when the Company completes a financing with minimum net proceeds of at least $4,000,000 and (b) July 1, 2016. The securities to be issued upon automatic conversion will be either the Company’s securities that are issued to the investors in the Financing or, if the Financing does not occur by July 1, 2016, shares of the Company’s common stock based on a conversion price of $0.312 per share. The debenture continues to bear interest at a rate of 8% per annum. The other material terms of the debenture were not changed.
	During the year ended December 31, 2013, the Company borrowed $448,475 under the LOC Convertible Debenture. As of December 31, 2013, the Company owed a balance of $448,475 in principal amount under the LOC Convertible Debenture, and there was $551,525 remaining available to use. As discussed in Note 10, in February 2014 the outstanding amount under the LOC Convertible Debenture, plus the interest accrued, were converted to shares of stock and the availability was reset at $1.0 million.
	The LOC Convertible Debenture contains a beneficial conversion feature of the note. The intrinsic value of the beneficial conversion feature at the date of issuance was determined by measuring the difference between the conversion price and the intrinsic value of the stock at the commitment date. The Company recorded a debt discount for the intrinsic value of the beneficial conversion feature which was limited to the proceeds with an offsetting increase to paid-in-capital. The beneficial conversion of $98,335 has been included in the balance sheet at December 31, 2013 as a discount to the related debt security, and is being accreted as non-cash interest expense over the expected term of the loan using the effective interest method.
	The Company recorded a total of $157,875 in debt discount for the amended debentures and LOC, and accreted $8,197 of the debt discount as interest expense.
	May 2013 Convertible Debt Instrument
	In May 2013, the Company issued convertible debt in the amount of $50,000, which, together with $1,458 of accrued interest, was converted in September 2013 into 83,103 shares of the Company’s common stock in accordance with the terms of the instrument, thereby fully extinguishing the debt.  During the five months that the debt was outstanding, the Company accreted $8,017 of the debt discount as interest expense.
	Interest Expense
	The Company recognized total interest expense on the January 2012 Debentures, the January 2013 Debenture and the LOC Convertible Debenture including amortization of the discount, of $67,246 and $17,031 for the year ended December 31, 2013 and 2012, respectively.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 6 –RELATED PARTY TRANSACTIONS
	Apricus Biosciences
	On October 4, 2012, the Company entered into a Settlement Agreement with Apricus Bio pursuant to which the Company sold to Apricus Bio its remaining fifty percent (50%) share of the future commercial right of PrevOnco, in exchange for the return of 135,888 shares of the Company’s common stock which Apricus Bio had acquired through the conversion of promissory notes issued by the Company and a one-time cash payment to the Company of $25,000.  In addition, the Company agreed to terminate its licensing right to the NexACT® technology and any claim to any PrevOnco backup compounds. There were no remaining transactions involving Apricus Biosciences at December 31, 2013 or 2012.
	Other
	On June 12, 2013, the Company entered into a subscription agreement for the sale of 416,841 shares of common stock at a purchase price of $0.3230 per share, which is the average closing price of the common stock over the 10-day trading period that ended on the day immediately prior to the date the Company entered into the subscription agreement. The Company received gross proceeds of approximately $134,640. The shares were issued to the Company’s President and Chief Executive Officer and his spouse (see Note 7).
	The Company has several convertible debentures outstanding to related parties (see Note 5).

SHAREHOLDERS_EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	NOTE 7 – SHAREHOLDERS’ EQUITY
	Capital Stock
	The Company is authorized to issue 150.0 million shares, all of which are common stock with a par value of $.001 per share.
	Issuances of Common Stock
	On January 17, 2013, the Company entered into an investor relations agreement with a third party pursuant to which the Company agreed to issue over the term of the agreement an aggregate of 250,000 shares of common stock in exchange for investor relations’ services to be rendered. On September 18, 2013, the Company extended the term of the investor relations agreement, and agreed to issue an additional aggregate of 300,000 shares of common stock in exchange for investor relations’ services to be rendered over the term of the agreement.
	As of December 31, 2013, the Company has issued the 250,000 shares according to the original agreement, and an additional 200,000 shares related to the extension. All issued shares have been valued at the closing price of the Company’s common stock on the date of issuance. The Company recognized expense of $229,950 under the investor relations agreement during the year ended December 31, 2013.
	On April 19, 2013, the Company issued 631,313 shares of common stock to CRI pursuant to the CRI Asset Purchase Agreement, which had a fair value of $250,000 (see Note 2).
	In connection with this transaction, the Company engaged a consultant to assist in the technology transfer and manufacturing of the product. In consideration of such services, the Company agreed to issue to the consultant shares of its common stock valued at $75,000 at various dates following the closing of the CRI transaction. For the year ended December 31, 2013, the Company has issued 227,302 shares. The value of the shares issued for the year ended December 31, 2013 was $75,000.
	On June 21, 2013, the Company issued an aggregate of 416,841 shares of common stock for proceeds of $134,639 to a related party.
	On June 28, 2013, the Company entered into an agreement with a consultant to provide drug development pre-clinical consulting services for CIRCUMserumTM and EjectDelay™.  In consideration of such services, the Company agreed to issue the consultant shares of its common stock valued at $80,200.  The number of shares to be issued will be determined based on the average of the closing price of the Company’s common stock for the 10 trading days immediately preceding the issue date.
	On August 29, 2013, the parties entered into an addendum to this consulting agreement.  In consideration of additional services, the Company agreed to issue the consultant shares of its common stock valued at an additional $23,000.   The number of shares to be issued will be determined based on the average of the closing price of the Company’s common stock for the 10 trading days immediately preceding the issue date.
	As of December 31, 2013, the Company has issued 236,547 shares according to the consulting agreement.  All issued shares have been valued at the closing price of the Company’s common stock on the date of issuance.  The aggregate value of the shares issued was $70,208, which corresponds to the service period of the consultant’s services.
	On May 15, 2013, the Company issued a convertible debt instrument in the amount of $50,000, which, together with $1,458 of accrued interest, was converted on September 25, 2013 into 83,103 shares of the Company’s common stock in accordance with the terms of the instrument, thereby fully extinguishing the debt.  During the five months that the debt was outstanding, the Company accreted $8,017 of the debt discount as interest expense.
	In addition, the Company issued 103,792 shares of common stock to other consultants under consulting agreements for the year ended December 31, 2013.  The shares were issued under the Company’s 2013 Equity Incentive Plan. All issued shares have been valued at the closing price of the Company’s common stock on the date of issuance.  The aggregate value of the shares issued was $181,891 for the year ended December 31, 2013, which corresponds to the service period of the respective consultant’s services.
	Equity Plan
	The Company has issued share-based stock, stock unit and option awards to employees, non-executive directors and outside consultants under the Company’s 2013 Equity Incentive Plan (the “Incentive Plan”), which was approved by the Board in February of 2013.  The Incentive Plan allows for the issuance of 10,000,000 shares of the Company’s common stock to be issued in the form of stock options, stock awards, stock unit awards, stock appreciation rights, performance shares and other share-based awards.  The exercise price for all equity awards issued under the Incentive Plan is based on the fair market value of the common stock.  Currently, because the Company’s common stock is quoted on the OTC Bulletin Board, the fair market value of the common stock is equal to the last-sale price reported by the OTC Bulletin Board as of the date of determination, or if there were no sales on such date, on the last date preceding such date on which a sale was reported.  Generally, each vested stock unit entitles the recipient to receive one share of Company common stock which is eligible for settlement at the earliest of their termination, a change in control of the Company or a specified date.  Stock units can vest according to a schedule or immediately upon award.  Stock options generally vest over a three-year period, first year cliff vesting with quarterly vesting thereafter on the three-year awards, and have a ten-year life.  Stock options outstanding are subject to time-based vesting as described above and thus are not performance-based.
	As of December 31, 2013, there were 6,300,000 stock units and 21,000 shares subject to options outstanding, the Company issued 567,641 shares as payments for services, and 3,100,109 shares were available for future grants under the Incentive Plan.
	Stock-based Compensation
	The stock-based compensation expense for the year ended December 31, 2013 was $2,254,898 for the issuance of stock units and stock options. The Company calculates the fair value of the stock units based upon the quoted market value of the common stock at the date of grant. The Company calculates the fair value of each stock option award on the date of grant using the Black-Scholes option-pricing model.  For the year ended December 31, 2013 the following weighted average assumptions were utilized for the stock option granted during the period:
		December 31, 2013
	Expected life (in years)		6
	Expected volatility		235.7%-240.6	%
	Average risk free interest rate		1.71%-2.10	%
	Dividend yield		0	%
	The dividend yield of zero is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. Expected volatility is based on the historical volatility of the Company’s common shares over the period commensurate with the expected life of the options. Expected life in years is based on the “simplified” method as permitted by ASC Topic 718. The Company believes that all stock options issued under its stock option plans meet the criteria of “plain vanilla” stock options. The Company uses a term of 6 years for all employee stock options. The risk free interest rate is based on average rates for 5 and 7 year treasury notes as published by the Federal Reserve.
	The following table summarizes the number of options outstanding and the weighted average exercise price:
						Weighted
						remaining
				Weighted average		contractual life	Aggregate
		Options		exercise price		(years)	intrinsic value
	Outstanding at December 31, 2012	-		$	-	-	$	-
	Granted	51,000			0.46	9.8		1,200
	Exercised	-			-	-		-
	Cancelled	-			-	-		-
	Forfeited	-30,000			-	-		-
	Outstanding at December 31, 2013	21,000		$	0.64	9.9	$	-
	Vested at December 31, 2013	21,000		$	0.64	9.9	$	-
	The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding options and the quoted price of the Company’s common shares that were in the money at December 31, 2013. At December 31, 2013 and 2012, the aggregate intrinsic value of all outstanding options was $0.
	The Company granted 51,000 options during the year ended December 31, 2013. The weighted average grant date fair value per share of options granted during the year ended December 31, 2013 was $0.46.
	Stock Units
	The following table summarizes the number of stock units outstanding:
		Stock Units
	Outstanding at December 31, 2012	-
	Granted	7,050,000
	Expired	-
	Cancelled	-750,000
	Forfeited	-
	Outstanding at December 31, 2013	6,300,000
	Vested at December 31, 2013	4,083,333
	The vested stock units at December 31, 2013 have not settled and are not showing as issued and outstanding shares of the Company. Settlement of these vested stock units will occur on the earliest of (i) the date of termination of service of the employee or consultant, (ii) change of control of the Company, or (iii) 10 years from date of issuance. Settlement of vested stock units may be made in the form of (i) cash, (ii) shares, or (iii) any combination of both, as determined by the committee.
	On February 15, 2013, the Company entered into a stock unit agreement with its President and Chief Executive Officer pursuant to his employment agreement. Under the terms of the agreement, the Company issued 6,000,000 stock units, 2,000,000 of the units vested immediately, while the remaining 4,000,000 vest in eight equal quarterly installments until January 1, 2015, subject to his continued service to the Company as of the vesting date.
	On February 15, 2013, the Company entered into a stock unit agreement with a consultant. Under the terms of the agreement, the Company issued 300,000 stock units, with one thirty-sixth of the units vesting on the 7th of each month beginning on March 7, 2013, subject to the consultant’s continued service to the Company as of the vesting date. At December 31, 2013, 83,333 shares have vested under this agreement.
	The Company recognized compensation expense of $2,254,898 for the vested portion of the stock units for the year ended December 31, 2013.
	Warrants
	The Company issued 380,973 warrants in connection with the Dawson James notes. The warrants have an exercise price of $0.10 and expire December 6, 2018. There were no exercises or additional issuances during the years ended December 31, 2012 or 2013.

NON_CASH_FINANCING_ACTIVITIES

NON CASH FINANCING ACTIVITIES	12 Months Ended
	Dec. 31, 2013
Non Cash Financing Activities Disclosure [Abstract]	'
Non Cash Financing Activities [Text Block]	'
	NOTE 8 – NON CASH FINANCING ACTIVITIES
	Non-cash financing activities are summarized as follows:
	Year ended December 31, 2013:
		⋅	The Company issued of 631,313 shares of common stock (valued at $250,000) in connection with the CRI Asset Purchase Agreement, as described in Note 3.
		⋅	The Company issued 83,103 shares of common stock upon conversion of a convertible note, as described in Note 7.
		⋅	The Company issued 3,201,776 shares of common stock for the acquisition of Semprae as described in Note 3.
	Year ended December 31, 2012:
		⋅	$74,668 payable to a related party was converted into a convertible note, as described in Note 5.
		⋅	The Company issued 135,888 shares of common stock related to the conversion of the Apricus Bio convertible promissory note that was originally issued in December 2011 and deemed contributed to capital in March 2012.
		⋅	A convertible debenture in the principal amount of $12,000 plus accrued interest of $435 was converted into 16,580 shares of common stock, as described in Note 5.
		⋅	Contingent liability in the amount of $28,926 was reclassified to equity due to expiration of the rescission rights, none of which were exercised.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	NOTE 9 – INCOME TAXES
	At December 31, 2013, the Company had net operating loss carry forwards of approximately $2,282,000 which may be offset against future taxable income through 2032. No net deferred tax assets are recorded at December 31, 2013 or 2012, as all deferred tax assets have been fully offset by a valuation allowance due to the uncertainty of future utilization.
	At December 31, 2013 and December 31, 2012, long term deferred tax assets consist of the following:
		2013		2012
	Net operating loss carry-forwards	1,165,000		251,000
	Equity based instruments	877,000		-
	Deferred compensation	155,000		-
	Intangibles	70,000		78,000
	Warrants	745,000		760,000
	Other	80,000		-
	Less: Valuation allowance	-3,092,000		-1,089,000
	Net deferred tax assets	-		-
	Pursuant to Section 382 of the Internal Revenue Code of 1986, the annual utilization of a company's net operating loss carryforwards could be limited if the Company experiences a change in ownership of more than 50 percentage points within a three-year period. An ownership change occurs with respect to a corporation if it is a loss corporation on a testing date and, immediately after the close of the testing date, the percentage of stock of the corporation owned by one or more five-percent shareholders has increased by more than 50 percentage points over the lowest percentage of stock of such corporation owned by such shareholders at any time during the testing period. The Company does not believe such an ownership change occurred subsequent to the reverse merger transaction.
	The Company has experienced an ownership change with regard to Semprae operating losses. Out of $19,482,000 of Federal and California NOLs, only $51,000 per year can be used going forward for a total of $1,032,000 each. The utilization of the Innovus net operating losses may be subject to various limitations under Internal Revenue Code 382.
	A reconciliation of the statutory federal income tax rate for the year ended December 31, 2013 to the effective tax rate is as follows:
	Expected federal tax	34	%
	State tax (net of federal benefit)	5.8
	Other	-0.1
	Valuation allowance	-39.7
	Total	-	%
	The Company follows FASB ASC 740-10, Uncertainty in Income Taxes. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense. The Company does not have any unrecognized tax benefits or a liability for uncertain tax positions at December 31, 2013 and 2012. The Company does not expect to have any unrecognized tax benefits within the next twelve months. The Company recognizes accrued interest and penalties associated with uncertain tax positions, if any, as part of income tax expense. There were no tax related interest and penalties recorded for 2013 and 2012. Since the Company incurred net operating losses in every tax year since inception, all of its income tax returns are subject to examination and adjustments by the IRS for at least three years following the year in which the tax attributes are utilized.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 10-SUBSEQUENT EVENTS
	January 12, 2012 Debenture Conversions
	On February 19, 2014, we agreed with all of the five holders of our outstanding 8% convertible debentures issued on January 12, 2012 and amended on January 23, 2013 and November 11, 2013 (“January 2012 Debentures”), to convert such debentures into shares of our common stock at a conversion price of $0.40 per share, and to terminate the January 2012 Debentures upon conversion. Immediately prior to conversion, the January 2012 Debentures had an aggregate principal and interest amount of $190,013, which was converted into 475,033 shares of our common stock and terminated.
	January 15, 2013 Debenture Conversion
	On February 19, 2014, we agreed with the holder of an 8% convertible debenture issued on January 15, 2013 (“January 2013 Debenture”) to convert such debenture on the same terms described above for the January 2012 Debentures. The principal and interest amount owed under the January 2013 Debenture immediately prior to conversion was $76,122, which was converted into 190,304 shares of our common stock and terminated.
	January 15, 2013 Line Of Credit Debenture Conversion
	On February 19, 2014, we agreed with the holder of an 8% convertible debenture line of credit (“LOC Debenture”) issued on January 15, 2013 to convert the current principal and interest owed under the LOC Debenture as of such date into shares of our common stock at a conversion price of $0.40 per share. The principal and interest amount owed under the LOC Debenture immediately prior to conversion was $476,165, which was converted into 1,190,411 shares of our common stock. The LOC Debenture will continue to exist outstanding in accordance with its terms and we may currently borrow up to $1 million under it.
	Securities Purchase Agreement
	On February 13, 2014, we entered into a Securities Purchase Agreement (the “SPA”) with an unrelated third party accredited investor pursuant to which we issued a convertible debenture in the aggregate principal amount of $330,000 (issued at an original issue discount of 10.0%) (the “SPA Debenture”) and a warrant to purchase 250,000 shares of our common stock (the “SPA Warrant”).
	The SPA Debenture is for the principal amount of $330,000, bears interest at the rate of 10% per annum and the principal amount and interest are payable on March 13, 2015 (the “Repayment Date”). The effective interest rate will be calculated considering the original issue discount and the warrants.
	The SPA Debenture may be converted in whole or in part at any time prior to the Repayment Date by the holder at a conversion price of $0.40 per share, subject to adjustment. We have the option to redeem the SPA Debenture before its maturity by payment in cash of 125% of the then outstanding principal amount plus accrued interest and other amounts due.
	The SPA Warrant provides the holder with the right to acquire up to 250,000 shares of common stock at an exercise price of $.50 per share, subject to certain adjustments as described in the SPA Warrant, at any time through the fifth anniversary of its issuance date.

ORGANIZATION_AND_SUMMARY_OF_SI1

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature Of Operations [Policy Text Block]	'
	Organization
	Innovus Pharmaceuticals, Inc., together with its subsidiaries (collectively referred to as “Innovus” or the “Company”) is an emerging pharmaceuticals company that delivers innovative and uniquely presented and packaged health solutions through its over-the-counter medicines and consumer and health products.  Innovus is located in La Jolla, California.  In its current state, the Company considers itself in a development stage but progressing into the commercial stage in the first quarter of 2014, based on the expected launch of two of its products for sexual dysfunction and arthritis pain relief in the US and other territories.
Corporate History [Policy Text Block]	'
	Corporate History
	Reverse Merger between North Horizon and FasTrack
	Innovus Pharma was incorporated as North Horizon, Inc. in 1959 as a Utah corporation and changed its domicile in 2007 to the State of Nevada. In December 2011, North Horizon merged with FasTrack Pharmaceuticals, Inc. North Horizon had no ongoing business at the time of the merger, and FasTrack had a pipeline of one commercial stage product, Apeaz, and one pre-clinical product candidate, Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1, or SSAO/VAP-1, antagonist intended for psoriasis and arthritis. A reverse merger occurred for financial reporting purposes, and the Company changed its name to Innovus Pharmaceuticals, Inc.
	Merger with Semprae Laboratories, Inc.
	On December 24, 2013, Innovus Pharma entered into an agreement and plan of merger (the “Merger Agreement”) with Innovus Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Innovus Pharma (“Merger Sub”), Semprae Laboratories, Inc., a Delaware corporation (“Semprae”), certain stockholders of Semprae and Quaker Bioventures II, L.P., a principal stockholder of Semprae, pursuant to which, on the same date, Merger Sub merged into Semprae with Semprae continuing as the surviving corporation and a wholly-owned subsidiary of Innovus Pharma.
	Proprietary Product and Technology Portfolios
	The Company is an emerging pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription pharmaceutical products and consumer care health products backed with strong scientific and clinical evidence. The Company’s products are focused in the men’s and women’s health and vitality, and in the pain management therapeutic categories.
	Pharmaceutical and Consumer Care Products
	Our pharmaceutical and consumer care product business is currently made up of over-the-counter (OTC) and consumer care health products. We are in the process of marketing our products in the US and other countries.
	EjectDelay
	EjectDelay™ is an OTC monograph compliant benzocaine based topical gel for treating premature ejaculation by desensitizing the nerves in the penis, allowing a man to delay ejaculation time.
	Apeaz™
	Apeaz™ is an OTC monograph compliant topical cream for the relief of arthritis pain among other inflammatory conditions which contains methylsulfonylmethane and glucosamine.
	CIRCUMserum™
	We acquired the foreign distribution rights to CIRCUMserum™, a non-medicated cream which moisturizes the head of the penis for enhanced feelings of sensation and greater sexual satisfaction from Centric Research Institute (“CRI”). CIRCUMserum is a patent-pending   blend of essential oils and ingredients generally recognized as safe that recently commenced marketing in the United States.
	Zestra® and Zestra® Glide
	We acquired Zestra® and Zestra® Glide, through the acquisition of Semprae Laboratories, Inc. Zestra® is a non-medicated patented natural product that helps with sexual dysfunction in women by increasing nerve conduction and vascular smooth muscle dilation, resulting in increasing desire, arousal in women. Zestra® Glide is a clinically tested water based lubricant.
	Xyralid™
	Xyralid™ is an OTC monograph compliant lidocaine based spray in development for the relief of hemorrhoids pain among other inflammatory conditions.
Basis Of Presentation And Principles Of Consolidation [Policy Text Block]	'
	Basis of Presentation and Principles of Consolidation
	These condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), and include all assets, liabilities, revenues and expenses of the Company and its wholly-owned subsidiary: FasTrack Pharmaceuticals, Inc.  All material intercompany transactions and balances have been eliminated. Certain items have been reclassified to conform to the current presentation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods.  Such management estimates include equity-based instruments, income taxes, realizability of deferred tax assets, and intangible assets. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions.
Liquidity Disclosure [Policy Text Block]	'
	Liquidity
	Historically, we have funded losses from operations through the sale of equity and issuance of debt instruments, primarily to related parties including directors and officers. Combined with minimal revenue, these funds have provided us with the resources to operate our business, to begin to sell and support our products, attract and retain key personnel, and add new products to our portfolio. To date, we have experienced net losses and negative cash flows from operations each year since our inception. Through December 31, 2013, we had an accumulated deficit of $6,405,000.
	As of December 31, 2013, we had $33,374 in cash and cash equivalents. We have raised funds through the issuance of convertible debentures and sale of common stock. We have also utilized equity instruments where possible to pay for services from vendors and consultants. Furthermore, we have an arrangement with our Chief Executive Officer which provides for a line of credit to us in the amount of up to $1,000,000  through the earlier of our successful completion of a financing of $4 million, or July 1, 2016 and permits the deferral of his salary payments as described below. Based upon these factors and arrangements, we believe our cash and cash equivalents will be sufficient to fund our operations until at least December 31, 2014. We expect that our short-term operating expenses will be primarily expenses to sell and support our products and attract and retain key personnel.
	Other potential sources of liquidity in the short term include payments from our existing partners for license fees, entering into new collaborative, licensing or commercial agreements in additional territories, and revenues from the sale of our products.
	In addition to payments from our current licensing and commercial agreements, as well as funds from public and private financial markets, potential sources of liquidity in the long term include milestone, royalty and other payments from any future commercial agreements or licensees and revenues from sales of our own products. If we determine it is advisable to raise additional funds, we do not know whether adequate funding will be available to us or, if available, that such funding will be available on acceptable terms.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair Value Measurement
	The Company’s financial instruments are cash, accounts receivable, accounts payable, accrued liabilities, convertible debentures and a convertible debt instrument. The recorded values of cash, trade accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. We believe the recorded values of convertible debentures and convertible debt, net of the discount, approximate the fair value as the interest rate (stated or effective) approximates market rates for similar types of instruments.
	The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows:
		⋅	Level 1 measurements are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
		⋅	Level 2 measurements are inputs other than quoted prices included in Level 1 that are observable either directly or indirectly.
		⋅	Level 3 measurements are unobservable inputs.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities of three months or less when purchased.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Credit Risk and Major Customers
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash held with financial institutions may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation (“FDIC”) on such deposits.
	Accounts receivable consist primarily amounts receivable from Ovation Pharma under our licensing agreement ( See note 4). The Company also requires a percentage of payment in advance for product orders with its larger partners. The Company has not yet recognized revenue under these arrangements. The Company also performs ongoing credit evaluations of its customers and generally does not require collateral.  There have been no write-offs of trade accounts receivable during the periods presented.
	The following table identifies customers with accounts receivable that individually exceed 10% of the Company’s total accounts receivable at December 31, 2013:
	Ovation Pharma		135,035		52	%
	Retail Customer A		37,963		15	%
Concentration Of Suppliers, Policy [Policy Text Block]	'
	Concentration of Suppliers
	The Company has manufacturing relationships with a number of vendors or manufacturers for its products including: CIRCUMserum™,  EjectDelay™,  Zestra® and the ApeazTM line of products.  Pursuant to these relationships, the Company purchases product through purchase orders with its manufacturers. The Company is in the process of entering into more formal agreements with certain of these manufacturers.
Business Combinations Policy [Policy Text Block]	'
	Business Combinations
	For business combinations the Company utilizes the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations. These standards require that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based on their respective fair values at the date of acquisition. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred.
	The Company recognizes separately from goodwill the fair value of assets acquired and the liabilities assumed. Goodwill as of the acquisition date is measured as the excess of consideration transferred and the acquisition date fair values of the assets acquired and liabilities assumed. While the Company uses its best estimates and assumptions as a part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the Company's estimates are subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may retroactively record adjustments to the fair value of the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company's consolidated statements of operations.
Inventory, Policy [Policy Text Block]	'
	Inventory
	Inventory, consisting primarily of finished goods, is valued at the lower of cost or market where cost is determined using the first-in, first-out method. The inventory balance at 2013 is primarily comprised of finished goods for Zestra® and Zestra® Glide from the acquisition of Semprae (See Note 3) . Inventory is shown net of obsolescence and allowance for reducing the inventory cost to market. Obsolescence of inventory is determined based on shelf life or potential product replacement.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment are recorded at historical cost less accumulated depreciation. Depreciation is computed using the straight-line method over their estimated useful lives. The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	'
	Intangible Assets
	Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives, which range in term from 7 to 14 years. The useful life of the intangible asset is evaluated each reporting period to determine whether events and circumstances warrant a revision to the remaining useful life.
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Goodwill
	The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit's carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significant!y i!npact those judgments in the future and require an adjustment to the recorded balances. The goodwill was recorded as part of the acquisition commenced on December 24, 2013. There was no impairment of goodwill for the year ended December 31, 2013.
	The purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired from Semprae. The final purchase price may be adjusted up to one year from the date of the acquisition. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below.
		⋅	The fair value of current assets and liabilities approximated their book value.
	The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. Such goodwill is not deductible for tax purposes and represents the value placed on entering new markets and expanding market share.
	Intangible assets consist of the following at December 31, 2013:
						Accumulated				Useful Lives
			Amount			Amortization		Net Amount		(years)
	Patents and trademarks		$	264,320		$	-722	$	263,598	14-Jul
	Customer contracts			611,119			-1,150		609,969	10
	CIRCUMserum™ license			250,000			-16,736		233,264	10
	Outstanding at December 31, 2013			1,125,439			-18,608		1,106,831
	Expected amortization is approximately $112,000 for each of the next five years, and $556,000 thereafter.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'
	Long-Lived Assets
	The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company evaluates assets for potential impairment by comparing estimated future undiscounted net cash flows to the carrying amount of the asset. If the carrying amount of the assets exceeds the estimated future undiscounted cash flows, impairment is measured based on the difference between the carrying amount of the assets and fair value.
Beneficial Conversion Features and Debt Discounts [Policy Text Block]	'
	Beneficial Conversion Features and Debt Discounts
	If a conversion feature of conventional convertible debt is not accounted for separately as a derivative instrument and provides for a rate of conversion that is below market value, this feature is characterized as a beneficial conversion feature (“BCF”). A BCF is recorded by the Company as a debt discount. The Company amortizes the discount to interest expense over the life of the debt using the effective interest rate method. The Company’s 8% convertible debentures and convertible line of credit contain an embedded conversion feature of the notes. (See Note 5)
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	Income taxes are provided for using the asset and liability method whereby deferred tax assets and liabilities are recognized using current tax rates on the difference between the financial statement carrying amounts and the respective tax basis of the assets and liabilities. The Company provides a valuation allowance on deferred tax assets when it is more likely than not that such assets will not be realized.
	The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting this standard, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognized interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying statements of operation. Accrued interest and penalties are included within the related tax liability in the consolidated balance sheets.
Revenue Recognition, Trade Receivables And Deferred Revenue, Policy [Policy Text Block]	'
	Revenue Recognition and Deferred Revenue
	The Company generates revenues from product sales and the licensing of the rights to market and commercialize its products.
	Product Sales. The Company ships product to its customers pursuant to purchase agreements or orders. Revenue from sales transactions where the buyer has the right to return the product shall be recognized at the time of sale only if (1) the seller’s price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the seller, or the buyer is obligated to pay the seller and the obligation is not contingent on resale of the product, (3) the buyer’s obligation to the seller would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the seller, (5) the seller does not have significant obligations for future performance to directly bring about resale of the product by the buyer and (6) the amount of future returns can be reasonably estimated.
	License Arrangements.  Payments received by the Company under license arrangements to market and commercialize its products may include non-refundable upfront fees, license fees, milestone payments for specific achievements designated in the agreements, and royalties on sales of products. The Company considers a variety of factors in determining the appropriate method of accounting under its license arrangements, including whether the various elements can be separated and accounted for individually as separate units of accounting.
Cost of Sales, Vendor Allowances, Policy [Policy Text Block]	'
	Sales Allowances
	The Company accrues for product returns, volume rebates and promotional discounts in the same period the related sale is recognized.
	The Company’s product returns accrual is primarily based on estimates of future product returns over the period customers have a right of return, which is in turn based in part on estimates of the remaining shelf-life of products when sold to customers. Future product returns are estimated primarily based on historical sales and return rates. The Company estimates its volume rebates and promotional discounts accrual based on its estimates of the level of inventory of its products in the distribution channel that remain subject to these discounts. The estimate of the level of products in the distribution channel is based primarily on data provided by the Company’s customers.
	In all cases, judgment is required in estimating these reserves, and actual claims for rebates, returns and promotional discounts could be materially different from the estimates.
	The Company provides a customer satisfaction warranty on all of its products to customers for a specified amount of time after product delivery. Estimated return costs are based on historical experience and estimated and recorded when the related sales are recognized. Any additional costs are recorded when incurred or when they can reasonably be estimated.
	The estimated reserve for sales returns and allowances, which is included in accounts payable and accrued liabilities, was insignificant at December 31, 2013 and December 31, 2012.
Cost of Sales, Policy [Policy Text Block]	'
	Cost of Goods Sold
	Cost of goods sold includes the cost of inventory, royalties and inventory reserves. The Company is required to make royalty payments based upon the net sales of its marketed products, Zestra® and CIRCUMserum ™.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Costs
	Research and development (“R&D”) costs, including research performed under contract by third parties, are expensed as incurred. Major components of R&D expenses consist of testing, clinical trials, material purchases and regulatory affairs.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-based Compensation
	The Company accounts for stock based compensation in accordance with ASC 718, Stock Based Compensation, which requires the recognition of the fair value of stock compensation as an expense in the calculation of net income. ASC 718 requires that stock-based compensation expense be based on awards that are ultimately expected to vest. Stock-based compensation for the years ended December 31, 2013 and 2012 have been reduced for estimated forfeitures. When estimating forfeitures, voluntary termination behaviors, as well as trends of actual option forfeitures, are considered. To the extent actual forfeitures differ from the Company’s current estimates, cumulative adjustments to stock-based compensation expense are recorded.
	Except for transactions with employees and directors that are within the scope of ASC 718, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.
Schedule of Share-based Compensation, Nonemployee Director Stock Award Plan, Activity [Table Text Block]	'
	Equity Instruments Issued to Non-Employees for Services
	Issuances of the Company’s common stock for services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants is determined at the earlier of (a) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) (b) the date at which performance is complete, and is based upon the quoted market price of the common stock at the date of issuance (See Note 7).
Comprehensive Loss, Policy [Policy Text Block]	'
	Comprehensive Loss
	Comprehensive loss consists of net loss and other gains and losses affecting stockholders’ equity (deficit) that, under U.S. GAAP, are excluded from net loss. Comprehensive loss was the same as net loss for the year ended December 31, 2013 and 2012 as the Company has no other comprehensive income.
Earnings Per Share, Policy [Policy Text Block]	'
	Earnings per Share
	Basic earnings per share are computed by dividing net loss by the weighted average number of common shares outstanding during the period presented. Diluted earnings per share are computed using the weighted average number of common shares outstanding during the periods plus the effect of dilutive securities outstanding during the periods. For the year ended December 31, 2013 and 2012, basic earnings per share are the same as diluted earnings per share as a result of the Company’s common stock equivalents being anti-dilutive.
	The following reconciliation shows the anti-dilutive shares excluded from the calculation of basic and diluted loss per common share attributable to the Company for the year ended December 31, 2013 and 2012:
			As of December 31
			2013		2012
	Gross number of shares excluded:
	Restricted stock units		6,300,000		-
	Stock options		21,000
	Convertible notes payable		2,378,287		2,853,360
	Warrants		380,973		380,973
	Total		9,080,260		3,234,333
New Accounting Pronouncements, Policy [Policy Text Block]	'
	New Accounting Pronouncements
	In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“AOCI”). This standard requires reporting, in one place, information about reclassifications out of AOCI by component. An entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of AOCI by the respective line items of net income, but only if the amount is reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified to net income in their entirety, an entity is required to cross-reference to other currently required disclosures that provide additional detail about those amounts. The information required by this standard must be presented in one place, either parenthetically on the face of the financial statements by income statement line item or in a note. The adoption of ASU 2013-02 had no impact on the Company’s financial position or results of operations.

ORGANIZATION_AND_SUMMARY_OF_SI2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Schedule of Product Information [Table Text Block]	'
	The following table identifies customers with accounts receivable that individually exceed 10% of the Company’s total accounts receivable at December 31, 2013:
	Ovation Pharma	135,035		52	%
	Retail Customer A	37,963		15	%
Schedule of Intangible Assets and Goodwill [Table Text Block]	'
	Intangible assets consist of the following at December 31, 2013:
					Accumulated				Useful Lives
		Amount			Amortization		Net Amount		(years)
	Patents and trademarks	$	264,320		$	-722	$	263,598	14-Jul
	Customer contracts		611,119			-1,150		609,969	10
	CIRCUMserum™ license		250,000			-16,736		233,264	10
	Outstanding at December 31, 2013		1,125,439			-18,608		1,106,831
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The following reconciliation shows the anti-dilutive shares excluded from the calculation of basic and diluted loss per common share attributable to the Company for the year ended December 31, 2013 and 2012:
		As of December 31
		2013		2012
	Gross number of shares excluded:
	Restricted stock units	6,300,000		-
	Stock options	21,000
	Convertible notes payable	2,378,287		2,853,360
	Warrants	380,973		380,973
	Total	9,080,260		3,234,333

BUSINESS_ACQUISITIONS_Tables

BUSINESS ACQUISITIONS (Tables)	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	'
	The aggregate purchase price consideration was as follows:
	Fair value of common stock issued to Semprae shareholders		$	960,530
	Fair value of royalty			308,273
	Net purchase price consideration		$	1,268,803
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
	The assets acquired and liabilities assumed at the transaction date are preliminary purchase price allocations based on the fair value and are summarized below:
	Cash and cash equivalents		$	3,749
	Accounts receivable			78,445
	Inventory			180,441
	Prepaid expenses			16,362
	Property and equipment			78,973
	Customer contracts			611,119
	Patents			99,894
	Trademarks			160,278
	Goodwill			421,372
	Accounts Payable			-38,330
	Debt			-343,500
	Net Purchase Price Consideration		$	1,268,803
	Common Stock			960,530
	Fair Market Value of Royalty			308,273
			$	1,268,803
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	'
	The pro forma data is for informational purposes only and may not necessarily reflect the actual results of operations had Semprae been operated as part of the Company since January 1, 2012.
			For the year		For the year
			ended December		ended December
			31, 2013		31, 2012
	Revenue		$	760,847	$	1,537,472
	Net Loss (1)			-4,375,108		-3,495,470
	Loss per common share -basic and diluted		$	-0.25	$	-0.23
	Shares used in computing net loss per common share			17,329,899		15,201,373
	-1	The pro forma net loss includes adjustments for interest expense related to the assumption of debt, and amortization expense related to the intangible assets acquired.

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2013
Notes Payable [Abstract]	'
Schedule Of Outstanding Unsecured Notes Payable [Table Text Block]	'
	The following table summarizes the outstanding unsecured notes payable at December 31, 2013 and 2012:
		2013		2012
	Dawson James Promissory Note	$	-	$	50,000
	Lourmarin Corporation Note		350,000		-
	January 2012 Debenture Holder- not amended (See Note 5)		20,000		-
	Promissory Notes		370,000		50,000

CONVERTIBLE_DEBENTURES_RELATED1

CONVERTIBLE DEBENTURES - RELATED PARTIES (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Convertible Debt [Table Text Block]	'
	The following table summarizes the outstanding unsecured convertible deberntures issued to related parties at December 31, 2013 and 2012:
		2013		2012
	January 2012 Debentures	$	142,668	$	162,668
	January 2013 Debenture		70,000		-
	Line of Credit- Convertible Debenture		448,475		-
	Debt Discount, net of accretion		-149,678
	Convertible Debentures- related parties		661,143		162,668

SHAREHOLDERS_EQUITY_Tables

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	'
	For the year ended December 31, 2013 the following weighted average assumptions were utilized for the stock option granted during the period:
		December 31, 2013
	Expected life (in years)		6
	Expected volatility		235.7%-240.6	%
	Average risk free interest rate		1.71%-2.10	%
	Dividend yield		0	%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes the number of options outstanding and the weighted average exercise price:
						Weighted
						remaining
				Weighted average		contractual life	Aggregate
		Options		exercise price		(years)	intrinsic value
	Outstanding at December 31, 2012	-		$	-	-	$	-
	Granted	51,000			0.46	9.8		1,200
	Exercised	-			-	-		-
	Cancelled	-			-	-		-
	Forfeited	-30,000			-	-		-
	Outstanding at December 31, 2013	21,000		$	0.64	9.9	$	-
	Vested at December 31, 2013	21,000		$	0.64	9.9	$	-
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	'
	The following table summarizes the number of stock units outstanding:
		Stock Units
	Outstanding at December 31, 2012	-
	Granted	7,050,000
	Expired	-
	Cancelled	-750,000
	Forfeited	-
	Outstanding at December 31, 2013	6,300,000
	Vested at December 31, 2013	4,083,333

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	At December 31, 2013 and December 31, 2012, long term deferred tax assets consist of the following:
		2013		2012
	Net operating loss carry-forwards	1,165,000		251,000
	Equity based instruments	877,000		-
	Deferred compensation	155,000		-
	Intangibles	70,000		78,000
	Warrants	745,000		760,000
	Other	80,000		-
	Less: Valuation allowance	-3,092,000		-1,089,000
	Net deferred tax assets	-		-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	A reconciliation of the statutory federal income tax rate for the year ended December 31, 2013 to the effective tax rate is as follows:
	Expected federal tax	34	%
	State tax (net of federal benefit)	5.8
	Other	-0.1
	Valuation allowance	-39.7
	Total	-	%

ORGANIZATION_AND_SUMMARY_OF_SI3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013
			Ovation Pharma [Member]	Retail Customer A [Member]
Accounts Receivable Net Current	$216,641	$0	$135,035	$37,963
Concentration Risk Percentage	'	'	52.00%	15.00%

ORGANIZATION_AND_SUMMARY_OF_SI4

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013
Intangible assets, Amount	$1,125,439
Intangible assets, Accumulated Amortization	-18,608
Intangible assets, Net Amount	1,106,831
Patents and trademarks [Member]	'
Intangible assets, Amount	264,320
Intangible assets, Accumulated Amortization	-722
Intangible assets, Net Amount	263,598
Customer contracts [Member]	'
Intangible assets, Amount	611,119
Intangible assets, Accumulated Amortization	-1,150
Intangible assets, Net Amount	609,969
Intangible assets, Useful Lives (years)	'10 years
CIRCUMserum license [Member]	'
Intangible assets, Amount	250,000
Intangible assets, Accumulated Amortization	-16,736
Intangible assets, Net Amount	$233,264
Intangible assets, Useful Lives (years)	'10 years
Maximum [Member]	'
Intangible assets, Useful Lives (years)	'14 years
Maximum [Member] | Patents and trademarks [Member]	'
Intangible assets, Useful Lives (years)	'14 years
Minimum [Member]	'
Intangible assets, Useful Lives (years)	'7 years
Minimum [Member] | Patents and trademarks [Member]	'
Intangible assets, Useful Lives (years)	'7 years

ORGANIZATION_AND_SUMMARY_OF_SI5

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	9,080,260	3,234,333
Restricted stock units [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,300,000	0
Stock options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	21,000	'
Convertible Notes Payable [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,378,287	2,853,360
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	380,973	380,973

ORGANIZATION_AND_SUMMARY_OF_SI6

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	Dec. 31, 2013	Jan. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Oct. 30, 2008	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
						Chief Executive Officer [Member]	Minimum [Member]	Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	'	'	'	'	'	'	'7 years	'14 years
Development Stage Enterprise, Deficit Accumulated During Development Stage	$6,405,000	'	$2,448,821	'	'	'	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year One to Five	112,000	'	'	'	'	'	'	'
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	556,000	'	'	'	'	'	'	'
Debt Instrument, Interest Rate, Effective Percentage	8.00%	13.00%	'	'	'	'	'	'
Cash	33,374	'	18,445	25,014	0	'	'	'
Proceeds from Issuance of Debt	'	'	'	'	'	4,000,000	'	'
Line of Credit Facility, Maximum Borrowing Capacity	$551,525	'	'	'	'	$1,000,000	'	'

LICENSE_AGREEMENTS_Details_Tex

LICENSE AGREEMENTS (Details Textual) (USD $)	12 Months Ended				12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Sep. 09, 2013	Sep. 09, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
		CIRCUMserum license [Member]	License Agreement Terms [Member]	Second License Agreement Terms [Member]	CRI Asset Purchase Agreement [Member]	CRI Asset Purchase Agreement [Member]	Ovation Pharma Agreements [Member]	Consultant [Member]
						Criteria One [Member]		CRI Asset Purchase Agreement [Member]
Maximum Milestone Payments	'	'	$11,250,000	$18,600,000	$7,000,000	'	'	'
Stock To Be Issued During Period For Services Value	250,000	'	'	'	250,000	200,000	'	'
Stock To Be Issued During Period For Services Shares	'	'	'	'	631,313	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'10 years	'	'	'10 years	'	'	'
Sales Revenue Ex US Sales	'	'	'	'	630	'	'	'
Common Stock Issued	'	'	'	'	'	'	'	75,000
License and Services Revenue	'	'	'	'	'	'	25,000	'
Finite-Lived Intangible Assets, Accumulated Amortization	($18,608)	($16,736)	'	'	'	'	'	'

BUSINESS_ACQUISITIONS_Details

BUSINESS ACQUISITIONS (Details) (Semprae Laboratories Inc [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Semprae Laboratories Inc [Member]	'
Business Acquisition [Line Items]	'
Fair value of common stock issued to Semprae shareholders	$960,530
Fair value of royalty	308,273
Net purchase price consideration	$1,268,803

BUSINESS_ACQUISITIONS_Details_

BUSINESS ACQUISITIONS (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
			Semprae Laboratories Inc [Member]
Business Acquisition [Line Items]	'	'	'
Cash and cash equivalents	'	'	$3,749
Accounts receivable	'	'	78,445
Inventory	'	'	180,441
Prepaid expenses	'	'	16,362
Property and equipment	'	'	78,973
Customer contracts	'	'	611,119
Patents	'	'	99,894
Trademarks	'	'	160,278
Goodwill	421,372	0	421,372
Accounts Payable	'	'	-38,330
Debt	'	'	-343,500
Net Purchase Price Consideration	'	'	1,268,803
Common Stock	'	'	960,530
Fair Market Value of Royalty	'	'	308,273
Net Purchase Price Consideration	'	'	$1,268,803

BUSINESS_ACQUISITIONS_Details_1

BUSINESS ACQUISITIONS (Details 2) (USD $)	12 Months Ended				62 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2013
Business Acquisition [Line Items]	'		'		'
Net loss	($3,956,179)		($236,515)		($6,546,239)
Loss per common share-basic and diluted (in dollars per share)	($0.23)		($0.02)		'
Shares used in computing net loss per common share (in shares)	17,329,899		11,999,597		'
Pro Forma [Member]	'		'		'
Business Acquisition [Line Items]	'		'		'
Revenue	760,847		1,537,472		'
Net loss	($4,375,108)	[1]	($3,495,470)	[1]	'
Loss per common share-basic and diluted (in dollars per share)	($0.25)		($0.23)		'
Shares used in computing net loss per common share (in shares)	17,329,899		15,201,373		'
[1]	The pro forma net loss includes adjustments for interest expense related to the assumption of debt, and amortization expense related to the intangible assets acquired.

BUSINESS_ACQUISITIONS_Details_2

BUSINESS ACQUISITIONS (Details Textual) (USD $)	9 Months Ended	12 Months Ended		62 Months Ended	0 Months Ended	12 Months Ended		12 Months Ended	0 Months Ended	1 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 07, 2011	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Oct. 04, 2012	Dec. 24, 2013	Dec. 31, 2013
					Fas Track Pharmaceuticals Inc [Member]	Fas Track Pharmaceuticals Inc [Member]	Fas Track Pharmaceuticals Inc [Member]	North Horizon Inc [Member]	Apricus Biosciences Inc [Member]	Semprae Laboratories Inc [Member]	Semprae Laboratories Inc [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Debt Conversion, Converted Instrument, Shares Issued	83,103	83,103	16,580	'	135,888	'	'	'	135,888	'	'
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	'	'	'	'	'	15,238,938	'	1,325,125	'	3,201,776	'
Percentage Of Issued And Outstanding Shares	'	'	'	'	'	'	'	'	'	15.00%	'
Outstanding Loan Amount Paid	'	'	'	'	'	'	'	'	'	$343,500	'
Loans Outstanding	'	'	'	'	'	'	'	'	'	640,000	'
Net Sales Annual Royalty Percentage	'	'	'	'	'	'	'	'	'	5.00%	'
Business Acquisition Equity Interest Issued Or Issuable Fair Value Per Share	'	'	'	'	'	'	'	'	'	$0.30	'
Business Acquisition Equity Interest Issued Or Issuable, Fair Value	'	'	'	'	'	'	'	'	'	'	960,530
Equity Method Investment, Ownership Percentage	'	'	'	'	'	'	92.00%	8.00%	'	'	'
Liability Due To Recapitalization	'	'	60,000	'	'	'	'	'	'	'	'
Percentage Of Ownership Interests	'	'	'	'	'	'	'	'	'	100.00%	'
Business Acquisition, Pro Forma Revenue	'	'	'	'	'	'	'	'	'	'	6,010
Business Acquisition, Pro Forma Net Income (Loss)	'	-6,331	'	'	'	'	'	'	'	'	'
Net loss	'	($3,956,179)	($236,515)	($6,546,239)	'	'	'	'	'	'	$6,331
Percentage Of Discount Rate	'	'	'	'	'	'	'	'	'	'	40.00%

NOTES_PAYABLE_Details

NOTES PAYABLE (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Promissory Notes	$370,000	$50,000
January 2012 Debenture [Member]	'	'
Promissory Notes	20,000	0
Dawson James [Member]	'	'
Promissory Notes	0	50,000
Lourmarin Corporation [Member]	'	'
Promissory Notes	$350,000	$0

NOTES_PAYABLE_Details_Textual

NOTES PAYABLE (Details Textual) (USD $)	12 Months Ended		62 Months Ended			0 Months Ended	1 Months Ended		1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jan. 31, 2013	Jan. 31, 2012	Dec. 06, 2012	Jan. 31, 2013	Dec. 07, 2011	Dec. 23, 2013
						Dawson James [Member]	Dawson James [Member]	Dawson James [Member]	Lourmarin Corp. [Member]
Notes Payable, Total	'	'	'	'	'	'	'	$50,000	'
Debt Conversion Conversion Price Discount Percentage	'	'	'	'	'	8.00%	'	'	'
Repayments Of Notes Payable	50,000	0	50,000	'	'	'	54,548	'	'
Debt Instrument, Interest Rate, Effective Percentage	8.00%	'	8.00%	13.00%	'	'	'	'	8.00%
Debt Instrument, Maturity Date	'	'	'	'	'	'	'	'	31-Aug-14
Convertible Promissory Notes Approved For Issuance	'	'	'	'	$174,668	'	'	'	$350,000

CONVERTIBLE_DEBENTURES_RELATED2

CONVERTIBLE DEBENTURES - RELATED PARTIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Line of Credit- Convertible Debenture	$448,475	$0
Debt Discount, net of accretion	-149,678	'
Convertible Debentures- related parties	661,143	162,668
January 2012 Debenture [Member]	'	'
Convertible Debentures- related parties	142,668	162,668
January 2013 Debenture [Member]	'	'
Convertible Debentures- related parties	$70,000	$0

CONVERTIBLE_DEBENTURES_RELATED3

CONVERTIBLE DEBENTURES - RELATED PARTIES (Details Textual) (USD $)

1 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Nov. 30, 2013

30-May-13

Jan. 31, 2013

Jan. 31, 2012

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Feb. 28, 2014

Feb. 13, 2014

Jan. 31, 2013

Dec. 31, 2013

6-May-13

Mar. 18, 2013

Jan. 22, 2013

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Jan. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

30-May-13

Dec. 31, 2012

Subsequent Event [Member]

Subsequent Event [Member]

Director [Member]

Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

One Holder [Member]

One Holder [Member]

Five Holder [Member]

January 2012 Debenture [Member]

January 2012 Debenture [Member]

January 2012 Debenture [Member]

January 2013 Debenture [Member]

January 2013 Debenture [Member]

January 2013 Debenture [Member]

Accured Interest [Member]

Accured Interest [Member]

Subsequent Event [Member]

Convertible Promissory Notes Approved For Issuance

'

'

'

$174,668

'

'

'

'

'

'

'

'

'

'

'

'

$74,668

'

'

'

'

'

'

'

'

'

Minimum Proceeds From Debt To Convert Securities

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

Debt Instrument, Interest Rate Increase

'

'

13.00%

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

Debt Conversion Convertible Instrument Share Price

$0.31

'

$0.05

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Amount

'

'

'

'

'

12,000

12,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument Interest Accrued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,458

435

Debt Conversion, Converted Instrument, Shares Issued (in shares)

'

'

'

'

83,103

83,103

16,580

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Expense, Related Party

'

'

'

'

'

67,246

17,031

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Debt

'

50,000

'

'

'

50,000

'

'

'

70,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

8.00%

'

'

'

'

8.00%

'

'

8.00%

'

'

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14-Jan-14

'

'

'

'

'

'

'

'

'

'

Requirement Of Additional Funds For Insufficient Liquidity Maximum Limit

'

'

'

'

'

'

'

'

'

'

'

1,000,000

500,000

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Fund Raised By Convertible Debentures Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'the holders funding commitment automatically terminated on the earlier of January 1, 2014 or when the Company completed a financing with minimum net proceeds of at least $500,000.

'

'

'

'

'

'

'

'

'

'

'

Long-term Line of Credit

'

'

'

'

'

448,475

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Debenture Approved For Issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

Requirement Of Additional Funds For Insufficient Liquidity, Description

'

'

'

'

'

'

'

'

'

'

'

'increase the maximum principal amount borrowable thereunder from $500,000 to $1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest and Debt Expense, Total

'

8,017

'

'

'

8,017

'

'

'

'

'

'

'

'

8,197

'

'

'

'

'

'

'

'

'

'

'

Line Of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

551,525

'

'

'

'

1,000,000

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Beneficial Conversion Feature

'

'

'

'

'

98,335

'

'

'

'

'

'

'

'

'

'

'

'

'

40,889

'

'

18,651

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

157,875

'

'

330,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other Notes Payable, Current

'

'

'

'

'

370,000

50,000

'

'

'

'

'

'

'

'

'

'

'

'

20,000

0

'

'

'

'

'

Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt

'

'

'

'

'

'

'

$1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)	0 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended		62 Months Ended	0 Months Ended		1 Months Ended	12 Months Ended
	Jun. 12, 2013	Jun. 30, 2013	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Oct. 04, 2012	Jun. 12, 2013	Jun. 21, 2013	Dec. 31, 2013
							Apricus Biosciences Inc [Member]	President and Chief Executive Officer [Member]	President and Chief Executive Officer [Member]	President and Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues	'	416,841	'	416,841	'	'	'	416,841	416,841	'
Stock Issued During Period Shares Price Per Share	$0.32	'	'	'	'	'	'	'	'	'
Proceeds From Issuance Of Common Stock	$134,640	'	'	$134,639	$100,500	$235,139	'	'	'	$134,640
Settlement Agreement, Transfer Of Future Commercial Right Percentage	'	'	'	'	'	'	50.00%	'	'	'
Debt Conversion, Converted Instrument, Shares Issued	'	'	83,103	83,103	16,580	'	135,888	'	'	'
Settlement Agreement, One Time Cash Payment	'	'	'	'	'	'	$25,000	'	'	'

SHAREHOLDERS_EQUITY_Details

SHAREHOLDERS' EQUITY (Details)	12 Months Ended
	Dec. 31, 2013
Expected life (in years)	'6 years
Dividend yield	0.00%
Maximum [Member]	'
Expected volatility	240.60%
Average risk free interest rate	2.10%
Minimum [Member]	'
Expected volatility	235.70%
Average risk free interest rate	1.71%

SHAREHOLDERS_EQUITY_Details_1

SHAREHOLDERS' EQUITY (Details 1) (USD $)	12 Months Ended		12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
			Employee Stock Option [Member]	Employee Stock Option [Member]
Stock Options, Outstanding Beginning Balance	'	21,000	0	'
Options, Granted	51,000	'	51,000	'
Options, Exercised	'	'	0	'
Options, Cancelled	'	'	0	'
Options, Forfeited	'	'	-30,000	'
Stock Options, Outstanding Ending Balance	6,300,000	21,000	21,000	0
Options, Vested	'	'	21,000	'
Weighted average exercise price, Outstanding Beginning Balance	'	'	$0	'
Weighted average exercise price, Granted	'	'	$0.46	'
Weighted average exercise price, Exercised	'	'	$0	'
Weighted average exercise price, Cancelled	'	'	$0	'
Weighted average exercise price, Forfeited	'	'	$0	'
Weighted average exercise price, Outstanding Ending Balance	'	'	$0.64	$0
Weighted average exercise price, Vested	'	'	$0.64	'
Weighted average remaining contractual life (years), Outstanding	'	'	'9 years 10 months 24 days	'0 years
Weighted average remaining contractual life (years), Granted	'	'	'9 years 9 months 18 days	'
Weighted average remaining contractual life (years), Vested	'	'	'9 years 10 months 24 days	'
Aggregate intrinsic value, Granted	'	'	$1,200	'
Aggregate intrinsic value, Outstanding	'	'	$0	$0

SHAREHOLDERS_EQUITY_Details_2

SHAREHOLDERS' EQUITY (Details 2)	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013
Stock Options, Outstanding Beginning Balance	'	21,000
Stock Units, Granted	51,000	'
Stock Options, Outstanding Ending Balance	6,300,000	21,000
Stock Units [Member]	'	'
Stock Options, Outstanding Beginning Balance	0	'
Stock Units, Granted	7,050,000	'
Stock Units, Expired	0	'
Stock Units,Cancelled	-750,000	'
Stock Units, Forfeited	0	'
Stock Options, Outstanding Ending Balance	6,300,000	'
Stock Units, Vested	4,083,333	'

SHAREHOLDERS_EQUITY_Details_Te

SHAREHOLDERS' EQUITY (Details Textual) (USD $)

1 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

62 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

30-May-13

Jun. 30, 2013

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Jun. 30, 2013

Apr. 30, 2013

Dec. 31, 2013

Apr. 30, 2013

Jun. 12, 2013

Jun. 21, 2013

Dec. 31, 2013

Dec. 31, 2013

Feb. 28, 2013

Dec. 31, 2013

Aug. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2013

Jan. 17, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 07, 2011

Dec. 31, 2012

Dec. 31, 2013

Employee Stock Option [Member]

Employee Stock Option [Member]

Common Stock [Member]

Common Stock [Member]

Consultant [Member]

Consultant [Member]

Consultant [Member]

CRI Asset Purchase Agreement [Member]

President and Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

President and Chief Executive Officer [Member]

Other Consultant [Member]

Stock Units [Member]

Stock Units [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Investor Relations Agreement [Member]

Investor Relations Agreement [Member]

Investor Relations Agreement [Member]

Investor Relations Agreement [Member]

Investor Relations Agreement [Member]

Fas Track Pharmaceuticals Inc [Member]

Apricus Bio Convertible Promissory Note [Member]

Dawson James [Member]

Shares Issued [Member]

Additional Shares Issued [Member]

Share-based Goods and Non-employee Services Transaction, Quantity of Securities Issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

250,000

200,000

'

'

'

Common Stock, Shares Authorized

'

'

'

150,000,000

150,000,000

'

150,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

250,000

'

'

'

'

'

Common Stock, Par Or Stated Value Per Share

'

'

'

$0.00

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issuance Expenses

'

'

'

$229,950

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement by Share Based Payment Award Options Vested In Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

83,333

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

'

'

51,000

'

'

'

51,000

'

'

'

'

'

'

'

'

'

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance

'

'

21,000

6,300,000

'

'

6,300,000

21,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services

'

'

'

'

'

'

'

567,641

'

1,017,641

134,364

'

'

227,302

631,313

'

'

'

103,792

'

'

'

236,547

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

416,841

'

416,841

'

'

'

'

'

'

'

'

'

'

'

416,841

416,841

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

'

'

'

'

3,100,109

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Future

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,254,898

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

'

'

'

$0.46

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

134,639

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation, Total

'

'

'

2,254,898

'

'

2,254,898

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Issued for Services

'

'

'

498,841

'

7,000

'

'

'

1,018

134

80,200

181,891

75,000

'

'

'

'

'

'

'

23,000

70,208

'

'

'

'

'

'

'

'

Convertible Debt

50,000

'

'

50,000

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Interest On Convertible Debt

'

'

'

1,458

'

'

1,458

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock To Be Issued During Period For Services Value

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued

'

'

83,103

83,103

16,580

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

135,888

135,888

'

Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures, Total

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value

'

'

'

0

0

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment Warrants, Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.10

Investment Warrants Expiration Date

'

'

'

6-Dec-18

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

'

'

380,973

'

'

380,973

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest and Debt Expense, Total

$8,017

'

'

$8,017

'

'

'

'

'

'

'

'

'

'

'

'

'

$8,197

'

'

'

'

'

'

'

'

'

'

'

'

'

NON_CASH_FINANCING_ACTIVITIES_

NON CASH FINANCING ACTIVITIES (Details Textual) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Debt Conversion, Converted Instrument, Shares Issued (in shares)	83,103	83,103	16,580
Debt Conversion, Original Debt, Amount	'	'	$74,668
Debt Conversion, Converted Instrument, Amount	'	12,000	12,000
Debt Instrument, Increase, Accrued Interest	'	'	435
Expiration Of Fastrack Rescission Offer Value	'	'	28,926
Stock Issued During Period Shares Issued For Asset Purchase	'	631,313	'
Stock Issued During Period Value Issued For Asset Purchase	'	250,000	'
Common Stock [Member]	'	'	'
Expiration Of Fastrack Rescission Offer Value	'	'	$14,722
Stock Issued During Period Shares Issued For Acquisition	'	3,201,776	'
Apricus Bio Convertible Promissory Note [Member]	'	'	'
Debt Conversion, Converted Instrument, Shares Issued (in shares)	'	'	135,888

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Net operating loss carry-forwards	$1,165,000	$251,000
Equity based instruments	877,000	0
Deferred compensation	155,000	0
Intangibles	70,000	78,000
Warrants	745,000	760,000
Other	80,000	0
Less: Valuation allowance	-3,092,000	-1,089,000
Net deferred tax assets	$0	$0

INCOME_TAXES_Details_1

INCOME TAXES (Details 1)	12 Months Ended
	Dec. 31, 2013
Expected federal tax	34.00%
State tax (net of federal benefit)	5.80%
Other	-0.10%
Valuation allowance	-39.70%
Total	0.00%

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013
Operating Loss Carryforwards	$2,282,000
Operating Loss Carryforwards, Limitations on Use	'through 2032
Net Operating Loss Carryforwards Federal And State	19,482,000
Net Operating Loss Carryforwards Federal and State Usable per year	51,000
Net Operating Loss Carryforwards Federal And State Outstanding Balance	$1,032,000

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)

12 Months Ended

1 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Feb. 13, 2014

Feb. 13, 2014

Feb. 13, 2014

Feb. 19, 2014

Feb. 19, 2014

Feb. 19, 2014

Feb. 28, 2014

Feb. 13, 2014

Feb. 28, 2014

Feb. 13, 2014

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Securities Purchase Agreement [Member]

January 2012 Debentures [Member]

January 2013 Debentures [Member]

LOC Debentures [Member]

SPA Debentures [Member]

SPA Debentures [Member]

SPA Warrant [Member]

SPA Warrant [Member]

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

10.00%

'

8.00%

8.00%

8.00%

'

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

$0.40

'

$0.40

'

$0.40

'

'

Debt Instrument Aggregate Principal And Interest

'

'

'

'

'

$190,013

$76,122

$476,165

'

'

'

'

Debt Instrument, Convertible, Carrying Amount of Equity Component

'

'

'

'

'

475,033

190,304

1,190,411

'

'

'

'

Debt Conversion, Converted Instrument, Amount

12,000

12,000

'

'

'

'

'

'

330,000

'

'

'

Warrants To Purchase Common Stock

'

'

'

'

'

'

'

'

'

'

250,000

'

Debt Instrument, Face Amount

$157,875

'

'

$330,000

'

'

'

'

'

'

'

'

Debt Instrument, Redemption Price, Percentage

'

'

'

'

'

'

'

'

125.00%

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

250,000

'

'

'

'

'

'

'

'

'

Shares Maximum Acquisition

'

'

'

'

'

'

'

'

'

'

'

0.5

Debt Discount Percentage

'

'

'

'

10.00%

'

'

'

'

'

'

'